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ABSTRACT OF THE DISSERTATION
TSLP-induced Mechanisms and Potential Therapies for
CRLF2 B-cell Acute Lymphoblastic Leukemia
by
Olivia L Francis
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, June 2015
Dr. Kimberly J Payne, Chairperson
Childhood CRLF2 B-cell Acute Lymphoblastic Leukemia (CRLF2 B-ALL) is a
high-risk form of leukemia that is associated with poor patient survival outcomes. CRLF2
B-ALL is five times more prevalent in Hispanic children than others and is associated
with a higher rate of relapse, thus contributing significantly to childhood cancer health
disparities. This disease occurs due to alterations of the CRLF2 gene, leading to overexpression of the CRLF2 protein- a component of the receptor signaling complex for the
cytokine Thymic Stromal LymphoPoietin (TSLP) on the surface of B-ALL cells. TSLP
has been shown to induce proliferation of human and mouse B-cell precursors via
activation of the JAK-STAT5 and more recently the PI3K/AKT/mTOR pathways.
However, the mechanisms by which TSLP-CRLF2 interactions contribute to high-risk
leukemia have not been elucidated. Therefore the objective of our studies was to
elucidate the TSLP-induced mechanisms that contribute to high-risk CRLF2 B-ALL and
to evaluate promising drug candidates to target high-risk B-ALL. Based on literature
findings and preliminary data, we hypothesized that TSLP contributes to CRLF2 B-ALL
by increasing proliferation and/or survival of leukemia cells via regulation of genes
downstream of CRLF2 pathway activation. This hypothesis was tested using experiments

xvi

developed under the following specific aims:- Aim 1: Optimize the novel hTSLP+/xenograft model for use in defining the role of TSLP in CRLF2 B-ALL; Aim 2: Identify
TSLP-induced cellular and molecular mechanisms that contribute to CRLF2 B-ALL;
Aim 3: Assess  candidate  drugs’  efficacy  against high-risk B-ALL. Results from the
studies conducted to address the specific aims show that 1) the hTSLP+/hTSLP- mouse
model produces detectable levels of hTSLP, which activates CRLF2 and expands normal
B-cells and activates the mTOR cell survival pathway in CRLF2 B-ALL cells in vivo; 2)
cellular assays of apoptosis along with gene expression data demonstrate that TSLP
regulates the expression of genes that promote cell death and survival of CRLF2 B-ALL
cells in vivo and in vitro; 3) drug efficacy studies performed on high-risk leukemia cells
using several drug candidates demonstrate that the Mcl-1 inhibitor MIM1 and the
Novomedix drug series induced cell death in CRLF2 B-ALL and Nalm6 cells
respectively. Taken together, the data provide evidence that TSLP regulates cell survival
mechanisms in CRLF2 B-ALL cells and provides a rationale for the use of combination
therapies that include drugs which target cell survival molecules and/or cellular functions
regulated by TSLP.
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CHAPTER ONE
INTRODUCTION
Normal B-cell Development
Stages of Early B-cell Differentiation
Human B-cells are derived from hematopoietic stem cells (HSCs) in the bone
marrow (BM), where they undergo lineage specific changes to develop into mature Bcells [1]. HSCs produce multi-potent progenitors (MPPs) which give rise to lymphoidprimed MPPs (LMPPs) followed by common lymphoid progenitors (CLPs). CLPs then
differentiate through the following consecutive B-cell stages to produce functional Bcells: Pro-B, Pre-B, Immature-B and Mature B (Figure 1.1)[2]. The pro-B to pre-B
transition requires successful rearrangement and expression of genes that encode the
immunoglobulin heavy chain (IGHµ), specifically the gene segments from the germ linevariable, diversity and joining regions during VDJ recombination [3-4]. This process is
facilitated by recombination activating genes 1 and 2 (RAG1 and RAG2) [3].
Approximately 1/3 of the pro-B cells successfully express the IgHµ chain and a surrogate
light chain (SLC) in their cytoplasm along with a pre-BCR on their surface, becoming
pre-B cells. This transition is often referred to as the first checkpoint [1, 5]. These pre-B
cells then undergo polyclonal expansion (proliferation of cells that have successfully
rearranged IGH) and prepare to rearrange their light chain.
The pre-B to immature-B transition is characterized by rearrangement of genes
that encode the immunoglobulin  light  chain  (Igκ  then  Igλ), and the suppression of SLC as
well as pre-BCR [1, 4]. This transition is the second checkpoint. Successful
rearrangements of both heavy and light chains contribute to the generation of a diverse
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antibody repertoire [3]. B-cells that fail to successfully rearrange and express functional
IgH and IgL chains are removed by programmed cell death also known as apoptosis[6].
The mature B-cells produced by this process express surface immunoglobulin M (IgM)
and subsequently undergo class switch recombination to produce a variety of antibody
isotypes (IgA, IgD, IgE, IgG) with high antigen specificity and affinity. The B-cells then
migrate to secondary lymphoid organs where they are able to mount a robust humoral
response against pathogens as part of the adaptive immune system machinery [7].

Fig.1.1 Stages of Early B-cell Differentiation

Cytokine Function in Normal B-cells
In order for the complex process of B-cell differentiation to occur, developing Bcells depend on extrinsic factors that are present in the BM microenvironment including
non-hematopoietic cells such as stromal cells and the factors that they secrete [8]. In the
bone marrow, B-cells associate with bone marrow stromal cells (BMSCs) which have
been described as progenitors of skeletal, muscle and neural tissues [9]. In addition to
their functions listed above, these BMSCs support the development of hematopoietic
(blood) cells including B-cells by secreting cytokines (growth factors) that are required
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for the B-cells to develop [1, 10]. Cytokines are peptides or glycoproteins that promote
cell growth, differentiation and/or survival [1].
CXCL12, Flt3, and interleukin 7 (IL-7) are among cytokines that are produced by
BMSCs and are required for the development of B-cells [1]. Specifically, IL-7 is required
for the survival, expansion and differentiation of mouse B-cell precursors [11-13]. Our
lab has demonstrated that IL-7 induces the expansion of human Pro-B cells, which is
crucial for providing large cell numbers to progress through the stages of B-cell
differentiation [14]. The cytokine Thymic Stromal Lymphopoietin (TSLP), which is
produced by epithelial cells of the lung and skin as well as BMSCs has also been shown
to contribute to B-development [15-16]. In addition to activating dendritic cells,
regulating inflammation and contributing to asthma and allergic responses; TSLP also
induces proliferation in human pro-B cells and promotes B-cell survival by protecting
cells from apoptosis, [17-20][Milford unpub. data].

TSLP and IL-7 Signaling in Normal B-cells
Cytokines interact with their receptors, which are often found on the
surface or within a cell, to activate signal transduction pathways and in turn promote cell
survival, proliferation and differentiation [10]. TSLP performs its function in B-cells by
binding to its receptor, which comprises of two subunits: IL-7Rα  and  TSLPR  (also  
known as CRLF2). Upon binding to its receptor, TSLP traditionally activates the JAKSTAT pathway [10, 21]. TSLP binds its receptor subunits, which dimerize leading to the
recruitment and activation of Janus kinases (JAK1 and JAK2) via cross-phosphorylation
followed by phosphorylation of tyrosine residues found in the cytoplasmic domain of the
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receptors [22]. Signal transducers and activators of transcription-STAT (primarily
STAT5) proteins- bind to the tyrosine-phosphorylated receptors via their SH2 domains
and become phosphorylated by the JAKs [22]. STATs then dissociate from the receptors,
form dimers, translocate to the nucleus and bind to the promoter of target genes in order
to regulate gene transcription. Studies have shown that STAT5 regulates B-cell survival
and differentiation; a process that is mediated by the Bcl2 family members [23]. More
recently, it has been shown that in addition to the JAK-STAT pathway, TSLP also binds
its receptor and signals through other downstream pathways such as the PI3K/AKT and
mTOR pathways [24-25][appdx]. It is important to note that IL-7 shares the IL-7Rα,  
which has implications for studies discussed later in this dissertation (Figure.1.2). To
perform its functions, IL-7 binds to its receptor which comprises of two subunits: IL-7Rα  
and IL-2Rγ  and  also  activates  the  JAK-STAT pathway [21]. IL-7 binds its receptor and
follows the signal transduction cascade described above for TSLP, with the exception
that IL-7 signals through JAK1 and JAK3 [22].

Fig.1.2 TSLP and IL-7 Receptors

The Role of Transcription Factors in Normal B-cells
Several transcription factors primarily Ikaros, PU.1, EBF, E2A and Pax5 all work
in concert to regulate the early stages of B-cell development (Figure 1.1)[26]. These
4

transcription factors function to activate or repress genes that are responsible for ensuring
B-cell lineage commitment during each stage of differentiation [26]. PU.1 regulates
lymphoid versus myeloid differentiation [2]. E2A maintains the stem cell pool, is
required to promote the lymphoid lineage at the LMPP and CLP stages and it turns on
and maintains the expression of EBF and Pax5 [27]. EBF regulates the genes that are
required for producing B-cells such as Pax5. Pax5 is absolutely required for maintaining
B-cell identity; in the absence of Pax5, cells de-differentiate to a progenitor stage where
they can commit to other lineages such as the T-lineage [28-29]. Ikaros promotes B-cell
development by regulating chromatin availability required for VDJ recombination,
regulating B-cell related genes and contributing to commitment to the B-lineage [2]. As a
result, B-cell differentiation is a tightly regulated process that is controlled by interactions
between transcription factors, the cytokines they regulate and the cellular processes that
occur during differentiation.

High-risk B-cell Acute Lymphoblastic Leukemia
Despite this tightly regulated process, aberrations can occur at various
developmental stages leading to B-cell related diseases such as lymphoma, autoimmune
diseases and leukemia [30-31]. Recent studies show that the dysregulation of genes
involved in B-cell differentiation, survival, proliferation and cell cycle contribute to
human leukemogenesis [32-35]. B-cell differentiation is blocked at the B-cell precursor
(BCP) stage where cells are rapidly proliferating due to genetic alterations in
transcription factors e.g. IKaros and Pax5, leading to the development of B-cell Acute
Lymphoblastic Leukemia (B-ALL) [36]. The loss of mechanisms that would normally
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induce apoptosis in B-cells that fail to differentiate, causes these aberrantly proliferating
cells to survive [37]. B-ALL is characterized by rapid accumulation of malignant B-cells
in the BM compared to other cell types.
Studies have identified several subtypes of B-ALL in which patients are resistant
to chemotherapy and suffer high rates of relapse, often resulting in death. These patients
are  referred  to  as  “high-risk” patients. High-risk patients are identified based on several
clinical features at diagnosis such as white blood cell count, age, ethnicity, cytogenic
abnormalities, response to treatment and minimal residual disease. After assessment, risk
classification schemes are used to place patients into low-risk, medium-risk or high-risk
categories [38]. Cytogenic abnormalities such as genetic mutations, genetic deletions and
chromosomal translocations are identified using genome wide association studies that
screen high-risk B-ALL patient samples [33, 39].
These studies proved useful in that they reported high-risk B-ALL patients as
having translocations such as BCR-ABL (also known as Philadelphia chromosomepositive (Ph+)) or mutations and/or deletions in the IKZF1 and CRLF2 genes [40-41] .
More recently, a high-risk subset of B-ALL was identified. This subset is referred to as
BCR-ABL-like or Ph-like ALL. Patients in this subset have a similar genetic profile to
Ph+ B-ALL, but lack the BCR-ABL fusion protein [41]. This subset is characterized by
an increased occurrence of IKZF1 gene defects and 50% of these patients have CRLF2
gene alterations [41]. The CRLF2 gene alterations include a translocation between the
IGH promoter and the CRLF2 gene producing a fusion transcript or an intrachromosomal deletion that forms a P2RY8-CRLF2 fusion transcript [41-42]. The CRLF2
genetic defects lead to the over-expression of the CRLF2 protein (the receptor component
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for TSLP) on the surface of B-ALL cells and this subset of B-ALL is referred to as
CRLF2 B-ALL.

Significance of Study
Identifying Molecular Targets in CRLF2 Signaling Pathway
ALL is the most common childhood malignancy and B-ALL accounts for 80% of
these cases [37]. With current therapies, ~25% of pediatric B-ALL patients still relapse
and ~15% of these children are most likely to fail therapy and die [38]. The high-risk Phlike B-ALL accounts for 10-15% of childhood B-ALL. Though Ph-like B-ALL has a
heterogeneous genetic profile (unlike Ph+ B-ALL), ~50% of this subset of B-ALL have
genetic defects in the CRFL2 gene [41]. The translocation leading to the BCR-ABL+ BALL subtype was the first of the genetic alterations to be identified and tyrosine kinase
inhibitors (TKIs) that specifically target the aberrant kinase activity produced by the
BCR-ABL translocation have been developed into drugs and are currently used to treat
patients [43-44]. This provides a paradigm for targeting pathways that are activated as a
result of genetic defects that are associated with high-risk leukemia. Despite the progress
made in relation to the survival outcomes of patients with the BCR-ABL translocation,
the survival outcomes of patients with CRLF2 gene defects continue to experience poor
survival outcomes. Further, the mechanism of disease and downstream molecular
mediators that contribute to CRLF2 B-ALL remains to be elucidated. The studies
described in the subsequent chapters of this dissertation are significant because they
identified molecular targets in the CRLF2 signaling pathway that regulate CRLF2 B-ALL
cell survival and can serve as druggable targets.
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Reducing Childhood Cancer Health Disparities
For ten years we have known that Hispanic children are more likely to develop
ALL (1.2 times more likely) and when they do, they are more likely to die (39% higher
death rate) when compared to other children [45]. Genome-wide association studies of
samples from high-risk B-ALL patients revealed that CRLF2 B-ALL is five times more
prevalent in Hispanic children and they experience a higher rate of relapse and an overall
poorer prognosis [46]. This is further accentuated in geographical locations where there is
a dense population of Hispanics such as California. Thus, over-expression of CRLF2 is
one of most significant biological components of childhood cancer health disparities
identified to date and is likely a major contributor to the increased incidence and higher
mortality rate for ALL in Hispanic children. Most of the health disparity studies
conducted so far focus on 1) examining the relationship between ethnicity and mortality;
2) the relationship between ethnicity and treatment outcomes and 3) the prevalence of
genetic defects and ancestry-related genetic alterations such as single nucleotide
polymorphisms [46-48]. The studies described in this dissertation are significant because
we identified TSLP-induced biological pathways and molecules that regulate the survival
of CRLF2 B-ALL, which is most prevalent among Hispanics. Additionally, the animal
model we developed provides a tool that can be used to study the mechanisms of CRLF2
B-ALL in Hispanic patient samples. The results from these studies offer the potential to
identify biological factors that contribute to the health disparity observed in Hispanic
children and can be targeted with appropriate therapies to improve survival outcomes,
thereby alleviating the disparity.
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Identifying Therapies to Target CRLF2 Signaling Pathway
Improved remission rates in recent years are primarily due to the administration of
higher doses of standard chemotherapy [49]. Despite the success of current therapeutic
strategies with some high-risk B-ALL such as Ph+ B-ALL, CRLF2 B-ALL patients still
experience a 65% relapse rate [34]. Therefore current treatment regimens have been
ineffective in reducing the relapse-rate of CRLF2 B-ALL. In addition, higher doses of
chemotherapy have resulted in increased toxicity and side effects for patients [50-52].
Imatinib, when used in combination with standard therapy, increased survival of children
with Ph+ B-ALL from ~35% to 80% [44, 53]. The  results  achieved  with  Imatinib’s  
ability to target the kinase in Ph+ B-ALL was ground breaking and provided a model that
can be followed in order to identify therapies to treat CRLF2 B-ALL. The studies
outlined in this dissertation are significant in that they identified therapeutic candidates
that exhibited efficacy on CRLF2 B-ALL and other high-risk B-ALL by targeting
molecular mediators of the CRLF2 signaling pathway and cellular processes. These drug
candidates show promise and have the potential to be used in combination with standard
therapy to increase efficacy of treatment for CRLF2 B-ALL.

Scientific Approach
Rationale
Studies in high-risk B-ALL including CRLF2 B-ALL, which were conducted by
Children Oncology Groups (COGs), have been directed towards genetic screening to
identify high-risk patients using risk stratification schemes [33, 38]. Additional studies
were conducted to assess CRLF2 B-ALL patient response to current treatment options
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and to determine therapeutic outcome, but very little is known about the cellular and
molecular mechanisms that contribute to the progression of the disease [34, 54]. Recent
molecular studies have shown that in some cases CRLF2 is associated with activating
mutations in JAKs that act downstream of TSLP-CRLF2 interactions. These activating
mutations have been shown to promote constitutive dimerization, constitutive JAK-STAT
activation and cytokine independent growth in the murine BAF3 cellular model system
[42, 55]. These data have led others to the conclusion that over-expression of CRLF2 and
activating JAK mutations are the major contributors to this disease suggesting that
CRLF2 B-ALL cells do not require TSLP-induced signals for survival and proliferation
due to constitutive activation of the JAK-STAT pathway. However, all JAK mutations
are not activating and 30% of CRLF2 B-ALL patients have no mutations in JAKs.
Our lab and others have shown that TSLP induces proliferation of normal human
B-cell precursors via activation of JAK-STAT or mTOR pathways [20, 24][TM unpub
data]. In addition, our lab has demonstrated that TSLP is produced by bone marrow
stromal cells and thus is present in the BM microenvironment where leukemia develops
[TM unpub data]. Our lab also showed that TSLP increases STAT5 phosphorylation in
CRLF2 B-ALL. These data provided a rationale for evaluating the role of the TSLPinduced CRLF2 signaling in the development and/or maintenance of CRLF2 B-ALL. Not
long after, Tasian, et al showed that stimulating primary CRLF2 B-ALL cells resulted in
what  they  termed  as  “aberrant”  activation  of  JAT-STAT and PI3K/mTOR signaling [25].
Further their studies confirmed that TSLP can indeed stimulate CRLF2 B-ALL cells with
or without JAK mutations thereby strengthening our rationale for conducting TSLPinduced studies. Additionally, in vivo studies to evaluate the efficacy of treatments for
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CRLF2 B-ALL are conducted in context of the presence or absence of JAK-mutations
and without TSLP-induced CRLF2 signals [56]. Thus, the contributions of TSLP (the
ligand that stimulates CRLF2 signaling) to the development, maintenance and/or
progression of CRLF2 B-ALL and the cellular and molecular mediators involved remain
to be fully elucidated. Therefore the objective of my dissertation studies was to elucidate
the TSLP-induced cellular and molecular mechanisms that contribute to CRLF2 B-ALL
and to identify promising drug candidates to target this disease.
Based on findings from the literature and data obtained from our lab, we
hypothesized that TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or
survival of leukemia cells via regulation of genes downstream of TSLP-CRLF2 pathway
activation. The hypothesis was tested conducting experiments according to three specific
aims and their respective sub-aims. Aim 1: Optimize the novel hTSLP+/- xenograft
model for use in defining the role of TSLP in CRLF2 B-ALL. Aim 1.1 Engineer
immune deficient mice to express human TSLP; Aim 1.2 determine whether CRLF2
pathways are activated in vivo in hTSLP+ mice. In Aim 2: Identify TSLP-induced
cellular and molecular mechanisms that contribute to CRLF2 B-ALL. Aim 2.1
compare apoptosis status of CRLF2 B-ALL cells from hTSLP+ and hTSLP- mice; Aim
2.2 identify pro-survival genes that are regulated by TSLP. Aim 3: Assess candidate
drugs’  efficacy  against  high-risk B-ALL. Aim 3.1 evaluate candidate cancer drugs for
in vitro efficacy in high-risk B-ALL; Aim 3.2 use the human-mouse xenograft model to
evaluate the in vivo efficacy of candidate drugs in high-risk B-ALL.
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Innovation
A Novel In-vivo Model to Identify TSLP-induced Molecular Mediators in CRLF2
B-ALL
Preliminary data from our lab shows that pediatric BM stromal cells express the
TSLP growth factor and thus provide an in vivo source of TSLP to stimulate CRLF2 BALL cells [TM unpub data]. Therefore it is important that in vivo studies to evaluate
therapies for CRLF2 B-ALL be performed in an in vivo model that includes TSLP, which
can stimulate activation of the CRLF2 signaling pathway in these cells. Human-mouse
xenograft models produced by injecting human leukemia cells into immune deficient
mice are the in vivo models of choice for identifying effective chemotherapies to treat
leukemia [57-58]. These models are possible because many growth factors and cytokines
produced in the mouse act on human cells. However, mouse TSLP does not stimulate
human CRLF2 [59]. Therefore standard xenograft models are inadequate for evaluating
the role of TSLP-induced signaling and downstream molecular mediators in CRLF2 BALL. Our lab has modified the human-mouse xenograft model currently used by other
researchers to produce a novel human TSLP+/– xenograft model system composed of
mice that express human TSLP (hTSLP+) or mice without human TSLP (hTSLP–) [60].
Studies shown in this dissertation include xenograft mice that were transplanted with
primary CRLF2 B-ALL cells taken from patient samples collected at the Loma Linda
University Medical Center (LLUMC) through collaboration with the Pediatric Oncology
Group (POG). These studies are innovative in that they are the first studies in which
human leukemia cells harvested from hTSLP+/hTSLP- xenograft mice were used to
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identify TSLP-induced in vivo cellular processes and molecular mediators in CRLF2 BALL.

New Therapeutics to Target the CRLF2-Signaling Pathway
CRLF2 B-ALL patients experience a high rate of relapse with current therapies.
We have ongoing collaborations with internal and external research groups that have
synthesized novel compounds to test for the treatment of high-risk B-ALL, including
CRLF2 B-ALL. Candidate drugs included the following: 1) Novomedix (NM) lead series
drugs: a series of small molecule drugs that have been shown to target cell cycle and
protein translation functions in cells; 2) Mcl-1 inhibitor: a small molecule inhibitor that
shows selective inhibition of the anti-apoptotic functions of the Bcl2 family member,
Mcl-1 [62]. These studies are innovative in that they explore novel therapeutic candidates
(in the case of the NM drugs) as well they utilize a novel approach of using known drug
candidates (such as the Mcl-1 inhibitor) to identify potential therapeutic candidates to
treat high-risk leukemia such CRLF2 B-ALL and Nalm6.

Tools and Models
CRLF2 B-ALL Cell Lines
Human CRLF2 B-ALL cell lines were used to study the role of TSLP stimulation
in CRLF2 B-ALL cells in vitro and in vivo as well as in drug efficacy studies. Cell lines
are easy to culture, thus they are excellent tools for performing cellular and molecular in
vitro studies.
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Primary CRLF2 B-ALL Cells
Even though cell lines are excellent tools, these cells may undergo changes over
time, which may make them different from the original cells taken directly from a patient.
Primary cells are difficult to culture and to manipulate, but they are the closest
representation of the patient condition, thus it is important to study these cells. Therefore
primary cells were also used to validate results. Primary cells were collected from
collaborations with Hematology Oncologists in the LLUMC under approved IRB
protocols.

HTSLP+/HTSLP- Xenograft Samples
Studies that assessed the effects of TSLP on CRLF2 B-ALL at the cellular and
molecular levels were conducted using CRLF2 B-ALL cell lines or primary cells that
were expanded in hTSLP+ and hTSLP- mice. These samples allowed us to compare
proliferation, apoptosis, gene expression and protein expression of human CRLF2 B-ALL
cells taken from an in vivo microenvironment containing human TSLP compared to those
taken from mice without TSLP.
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CHAPTER TWO
A NOVEL XENOGRAFT MODEL TO STUDY THE ROLE OF TSLP-CRLF2
SIGNALS IN NORMAL AND MALIGNANT HUMAN B-LYMPHOPOIESIS

Abstract
The cytokine, TSLP, stimulates in vitro proliferation of human fetal B cell
progenitors, however, its in vivo role during normal human B lymphopoiesis is unknown.
Genetic alterations that cause overexpression of the TSLP receptor component, CRLF2,
lead to B cell acute lymphoblastic leukemia (CRLF2 B-ALL), implicating the TSLPCRLF2 pathway in leukemogenesis. Engineered cellular models suggest that mouse
TSLP is unlikely to activate human CRLF2-mediated signals, limiting the utility of
classic human-mouse xenografts for studies of the TSLP-CRLF2 pathway in normal and
malignant B lymphopoiesis. First, we show that mouse TSLP does not induce activation
of the CRLF2 downstream pathways (JAK/STAT5 and PI3K/AKT/mTOR) that are
activated by human TSLP (hTSLP) in CRLF2 B-ALL cells. Next, we engineered
xenograft mice to produce hTSLP (+T mice) by transplantation with stromal cells
transduced to express hTSLP. Controls (–T mice) were produced by transplantation with
stroma transduced with a control vector. Normal serum levels of hTSLP were achieved in
+T mice, while hTSLP was undetectable in –T mice. hTSLP produced by +T stroma
induced JAK/STAT5 and PI3K/AKT/mTOR pathway activation and showed functional
in vivo effects on normal human B cell progenitors and primary CRLF2 B-ALL cells.
Gene expression profiling of primary CRLF2 B-ALL cells showed an induction of
mTOR regulated gene expression and increased TSLP-regulated gene responsiveness
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when cells were expanded in +T as compared to –T mice. The novel +T/–T xenograft
model developed here provides a tool for understanding the role of the TSLP-CRLF2
pathway in normal and malignant hematopoiesis.
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Abbreviations
B-ALL

B-cell Acute Lymphoblastic Leukemia

TSLP

Thymic Stromal Lymphopoietin

CRLF2

Cytokine Receptor-Like Factor 2

JAK

Janus Kinase

STAT5

Signal Transducer and Activator of Transcription 5

mTOR

Mammalian Target Of Rapamycin

PDX

Patient Derived Xenograft

PI3K

Phosphoinositide-3-Kinase

AKT

Protein Kinase B

IL-7R

Interleukin 7 Receptor alpha chain

mTSLP

Mouse TSLP

hTSLP

Human TSLP

S6

Ribosomal protein S6

NSG

NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ)

BM

Bone Marrow

HS27

Human Stroma 27 (bone marrow stromal cell line)
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Introduction
TSLP plays key roles at several points in normal hematopoietic cell development
and function, including early stages of B cell development (1-4). TSLP is an IL-7-like
cytokine that can replace IL-7 in stimulating the expansion of murine B cell precursors
(5, 6). The role of TSLP in the production of human B cells is less clear, although it has
been shown to support the proliferation of human fetal B cell progenitors (7, 8). Genetic
alterations that cause overexpression of a TSLP receptor component, CRLF2, have been
linked to B cell acute lymphoblastic leukemia (B-ALL), thus implicating the TSLP
pathway in leukemogenesis (9-12).
B-ALL is the most common childhood malignancy (13-15) and despite advances
in treatment strategies, ~25% of pediatric B-ALL patients relapse (16). Genomic
profiling studies have identified several high-risk B-ALL subtypes that are resistant to
chemotherapy (17-20). CRLF2 B-ALL is a high-risk subtype characterized by alterations
of the CRLF2 gene leading to over-expression of the CRLF2 protein on the surface of BALL cells (9-12). CRLF2 and the IL-7 receptor alpha chain (IL-7R ) together form a
cytokine receptor signaling complex that is activated by TSLP (Figure 2.1) (6, 21).
Binding of TSLP induces CRLF2 to dimerize with the ILactivation of the JAK-STAT5 pathway (22, 23) as well as the PI3K/AKT/mTOR pathway
(24, 25). The finding that JAK kinases are mutated in CRLF2 B-ALL (26) suggested that
CRLF2 and mutated JAK cooperate to induce constitutive STAT5 activation in CRLF2
B-ALL (27, 28). However, approximately half of CRLF2 B-ALL lack JAK mutations.
Thus, the role of TSLP in CRLF2 B-ALL remains unclear.
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Fig. 2.1: Pathways activated downstream of TSLP receptor signaling in human cells.

Patient-derived xenograft (PDX) models produced by injecting human cells into
immune deficient mice provide in vivo preclinical models for understanding disease
mechanisms and identifying effective therapies. However, the available data (6) suggests
that TSLP produced in the mouse (mTSLP) is unlikely to stimulate CRLF2-mediated
signaling in human cells. Given the role of TSLP in activating the CRLF2 pathway and
the downstream proliferation of human B cell progenitors, it will be important that
studies to identify disease mechanisms and potential therapies for CRLF2 B-ALL be
performed in preclinical models that provide human TSLP (hTSLP).
Here we describe the development of a novel xenograft model system comprised
of mice that provide hTSLP (+T mice) and mice that do not (–T mice). +T xenograft
mice show functional in vivo hTSLP effects, expanding the production of normal B
lineage cells from hematopoietic stem cells and inducing changes in mTOR-regulated
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gene expression in primary CRLF2 B-ALL cells. The +T/–T xenograft model system
provides an important new model for understanding the role of TSLP in normal and
malignant B lymphopoiesis.

Materials and Methods
Human Samples and Cell Lines
Human CRLF2 B-ALL cell lines MUTZ5 and MHH-CALL4 were purchased
from DSMZ (Braunschweig, Germany). The human stromal cell line HS27 was
purchased from ATCC (Manassas, VA). Primary human CRLF2 B-ALL cells and
umbilical cord blood (CB) were obtained in accordance with protocols approved by the
Loma Linda University Institutional Review Board (IRB) and with the Helsinki
Declaration of 1975, as revised in 2008. CD34+ cells were isolated from CB as described
in companion paper. Culture media are described in the online supplementary methods.

Mice
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory). Mice were housed under pathogen-free conditions in the Loma
Linda University Animal Care Facility and studies were conducted in accordance with
Loma Linda University Institutional Animal Care and Use Committee (IACUC)
approved protocols.

Flow Cytometry
Cells were prepared for flow cytometry to detect surface antigens using protocols
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described in companion paper. Details of phospho-flow cytometry and specific antibody
clones and conjugates are described in online supplementary methods. Flow cytometry
analysis was performed using a MACSQuant analyzer (MiltenyiBiotec, Inc, Auburn, CA)
and Flowjo flow cytometry data analysis software (TreeStar, Ashland, OR)

Stromal Cell Transduction
Human HS27 stromal cells were transduced to express hTSLP (+T stroma) or
with control vector (–T stroma) at a multiplicity of infection of 0.5-5/cell overnight. After
transduction, cells were washed, expanded in culture, and frozen in aliquots. For the
generation of +T and –T mice, stromal cells were thawed, cultured, and injected into
mice within 15 passages after thawing. Details of lentiviral vector production and
ELISAs to determine hTSLP levels are available in online supplementary methods.

Xenograft Transplantation
HS27 stroma that were transduced to be +T or –T were injected intraperitoneally
into NSG mice at doses of 5 or 10x106 cells at time points described in the results section.
Mice were sub-lethally irradiated with 225 cGy, then transplanted by tail vein injection
with freshly thawed human umbilical cord blood CD34+ cells (1x105) or primary CRLF2
B-ALL (5x105) cells.

Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells
Microarray analysis of gene expression in patient-derived CRLF2 B-ALL cells
following TSLP stimulation in vivo and ex vivo were  performed  by  Miltenyi  Biotec’s  
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Genomic Services (Miltenyi Biotec GmbH, Bergisch Gladbach) using Agilent Whole
Human Genome Oligo Microarrays (Design ID 039494, 8x60K v2). Gene Set
Enrichment Analysis (GSEA) was performed by Novogenix Laboratories, LLC (Los
Angeles, CA). Details of microarray assays, data processing, differential gene expression
analysis, GSEA, Ingenuity Pathway Analysis (IPA) and quantitative RT-PCR analysis are
described in the online supplementary methods. The data discussed in this publication
have been deposited in NCBI's Gene Expression Omnibus (29) and are accessible
through GEO Series accession number GSE65274
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE65274).

Results
Mouse TSLP does not Activate the Human TSLP Receptor Complex
Activation of the human TSLP receptor complex can be induced by hTSLP, but
not by mTSLP, in murine Ba/F3 cells transduced to express human CRLF2 and IL-7Rα  
(6). These data suggest that mTSLP is unlikely to activate human CRLF2-mediated
signals in human-mouse xenograft models. However, the ability of mTSLP to activate
CRLF2- signaling in human cells, particularly those expressing high levels of CRLF2
observed in CRLF2 B-ALL, has not been reported. To determine if mTSLP can induce
CRLF2-mediated signals we tested its ability to activate downstream pathways in human
CRLF2 B-ALL cells. First, we verified that the CRLF2 B-ALL cell lines and primary
CRLF2 B-ALL cells used in our studies express both of the TSLP receptor components.
Expression of IL-7Rα,  as well as high levels of CRLF2, was observed in both CRLF2 B-
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ALL cell lines and in the primary CRLF2 B-ALL cells used in studies described here
(Figure 2.2).

Figure 2.2: CRLF2 B-ALL cell lines (MUTZ5, MHH-CALL4) and primary CRLF2 BALL cells used to produce patient-derived xenografts (PDX) used in the studies described
here were stained for flow cytometry to detect the TSLP receptor components (IL-7Rα  and  
CRLF2). Plotted are cells within living cell light scatter. Quadrants shown were set based
on isotype controls.

Next we used phospho-flow cytometry to determine whether mTSLP can activate
the JAK-STAT5 and PI3K/AKT/mTOR pathways activated by hTSLP in CRLF2 B-ALL
cells (30). Although hTSLP induced clear increases in phosphorylated STAT5 (pSTAT5)
in CRLF2 B-ALL cell lines and primary CRLF2 B-ALL cells, mTSLP showed no effect
(Figure 2.3).
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Figure 2.3: CRLF2 B-ALL cell lines and CRLF2 B-ALL cells from a PDX generated from
the primary cells in panel C were stimulated with human TSLP (hTSLP) and mouse TSLP
(mTSLP) at 15ng/ml, or no cytokine and evaluated for phosphorylated STAT5 (pSTAT5)
AKT (pAKT), and S6 (pS6) by intracellular phospho-flow cytometry.

Stimulation of CRLF2 B-ALL cells with mTSLP also failed to increase
phosphorylated AKT (pAKT), while hTSLP produced modest increases (Figure 2.3). The
ribosomal protein S6 is phosphorylated downstream of mTOR activation (31) and a
robust induction of phosphorylated S6 (pS6) was observed in CRLF2 B-ALL cells
stimulated with hTSLP (Figure 2.3). In contrast, no increases in pS6 were observed when
cells were stimulated with mTSLP (Figure 2.3). Taken together, these data show that
mTSLP fails to induce the STAT5, AKT, or S6 phosphorylation that are characteristic of
CRLF2-mediated signals induced by hTSLP in human CRLF2 B-ALL cells. Thus, TSLP
produced in the mouse cannot induce human CRLF2-mediated signals in existing humanmouse xenograft models.
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Engineering Xenograft Mice to Express Normal Serum Levels of Human TSLP
We developed a strategy for engineering xenograft mice that can provide hTSLP
to activate CRLF2-mediated signals (Figure 2.4). Expression of human cytokines in
xenograft mice has been achieved by transplanting mice with human stromal cells (32).
Our strategy was to build on this approach and engineer immune deficient NSG mice that
express stable, sustained serum levels of hTSLP similar to normal reported levels in
children (range 13-32 pg/ml (33)). This would be achieved by intraperitoneal injection of
stromal cells transduced to express high levels of hTSLP. Human HS27 stromal cells
were transduced with lentiviral vector containing hTSLP (+T stroma) or with control
vector (–T stroma).

Figure 2.4: Strategy for developing the +/–hTSLP xenograft model: 1) HS27 stromal cells
transduced with a lentiviral vector to express hTSLP (+T) or with empty vector control (–
T). 2) Transduced stroma intraperitoneally injected to produce +T and –T NSG mice. 3)
Human cells injected to produce xenograft mice with hTSLP (+T xenograft mice) and
without hTSLP (–T xenograft mice)

Supernatant collected from stroma after multiple passages following the initial
transduction with hTSLP was evaluated by ELISA and showed TSLP levels of ~500
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pg/ml (Figure 2.5, transduction 1). The ability of +T stroma to generate measureable
serum levels of TSLP in vivo was evaluated. NSG mice receiving weekly intraperitoneal
injections of 5X106 +T stroma showed serum hTSLP levels that were low but detectable
(4-10 pg/ml; data not shown) as measured by ELISA. To achieve higher levels of
sustained hTSLP expression NSG mice were injected with 3 doses of 1X107 +T or –T
stroma over a 1 week period (loading dose) followed by weekly injections of 1X107
stromal cells. Serum was collected at weekly time points and hTSLP levels were
evaluated by ELISA. The initial 3 doses of stroma gave serum TSLP levels that were ~80
pg/ml which quickly dropped to 15-20 pg/ml with weekly injections of +T stroma (Figure
2.6, transduction 1). hTSLP was not detectable in the sera of mice transplanted with –T
stroma (Figure 2.6, transduction 1). These data show that +T stroma can generate normal
serum levels of hTSLP and that serum levels of hTSLP correspond to the number of
stromal cells injected during the previous one to two week period. Thus, the loading dose
that allowed us to achieve normal serum levels resulted in an initial spike in hTSLP
rather than stable sustained levels of serum hTSLP that we had hoped to achieve. These
data suggested that stable, sustained TSLP production might be more likely with weekly
injections of stroma that could deliver slightly higher doses of TSLP.
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Figure 2.5: Culture supernatant from HS27 +T and HS27 –T stromal cells was assessed by
ELISA to determine levels of hTSLP protein produced by HS27 cells from transduction 1
(+T only). Supernatant from transduction 2 was collected at early (passage 1-5), mid
(passages 6-10) and late (passages 11-15) post thaw passages and hTSLP levels were
evaluated by ELISA.
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Figure 2.6: Serum levels of hTSLP in blood collected at indicated time points from +T or
–T mice injected with stroma as determined by ELISA were as follows: C) loading dose (3
doses of 1X107 in first week) followed by weekly doses of 1X107 stromal cells
(transduction 1 cells), graphed are the means ± SEM of n = 2-7 mice at each time point. D)
injection of 5X106 stromal cells (transduction 2) at weekly intervals; graphed are the means
± SEM n ≥  24  mice  at  each  time  point.  

A second stromal cell transduction was performed. Supernatant was collected at
each passage for evaluation of hTSLP protein expression by ELISA. Stable production of
hTSLP averaging ~900 pg/ml was observed at early, mid and late passages in +T stroma
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across multiple thaws of frozen aliquots from the second transduction (Figure 2.5,
transduction 2). hTSLP was undetectable in supernatant from similarly passaged –T
stroma (Figure 2.5, transduction 2). NSG mice transplanted at weekly time points with
5X106 stroma from transduction 2 showed serum hTSLP levels of approximately 20
pg/ml that were stable up to 11 weeks (Figure 2.6, transduction 2 and data not shown). To
verify that the hTSLP produced in our model induces CRLF2-mediated signals, we
assessed CRLF2 B-ALL cell lines for activation of the JAK/STAT5 and
PI3K/AKT/mTOR pathways by phospho-flow cytometry. Supernatant from +T stroma
induced robust pSTAT5 and pS6 and minimal pAKT (Figure 2.7). In contrast, CRLF2 BALL cells stimulated with supernatant from –T stroma showed background levels of
pSTAT5, pAKT, and pS6, similar to levels observed in cells incubated with medium
alone (Figure 2.7). These data show that +T stroma, but not –T stroma used in our model
produce hTSLP that can activate signaling in human CRLF2 B-ALL cells.
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Figure 2.7: CRLF2 B-ALL cell lines were stimulated with stromal cell supernatant and
levels of pSTAT5, pAKT and pS6 were measured by intracellular phospho-flow cytometry.

HTSLP Produced in Xenograft Mice Shows Functional Effects on Normal Human
B-lineage Cells
Next we evaluated the ability of hTSLP in +T mice to induce functional effects in
human B lineage cells in vivo. Normal B cell precursors respond to direct stimulation by
TSLP ((4) and companion paper, Figure 1), despite their low levels of CRLF2 expression
((4) and Figure S1-Appdx A), and thus provide a sensitive in vivo functional test of the
hTSLP produced in our xenograft model. To test our xenograft model we compared
normal B cell production in +T and –T NSG mice transplanted with umbilical CB CD34+
cells followed by weekly injections of +T and –T stroma (Figure 2.8A). Five weeks posttransplant mice were euthanized and bone marrow (BM) was harvested for flow
cytometry to evaluate the production of B lineage and other hematopoietic cells. Mouse
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and human cells were identified based on expression of mouse CD45 (mCD45) and
human CD45 (hCD45) respectively (Figure 2.8B). Levels of human cell engraftment
were high (>90%) in +T and –T animals, consistent with what we have previously
observed in NSG mice transplanted with CB CD34+ cells (Su, unpublished data).
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Figure 2.8 A-C: hTSLP produced in +T xenograft mice shows functional effects on normal
human B lineage cells. A) –T and +T NSG mice were transplanted with 1 X 105 CD34+
human cord blood (CB) cells and injected with weekly doses of 1X107 stromal cells. B)
Five weeks post-transplant, mice were euthanized, BM harvested and cells were stained
for flow cytometry to detect mouse CD45 (mCD45), human CD45 (hCD45), and hCD19.
Total living cells were gated mCD45 vs. hCD45 is plotted with gates to identify mouse and
human leukocytes respectively, in the BM. C) hCD45+ cells were gated and hCD19
expression is shown by histogram. Percents are mean + SEM.

TSLP has been shown to increase the in vitro production of human B cells ((4)
and companion paper). To determine if hTSLP levels achieved in vivo in +T mice could
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exert functional effects on normal human B lineage cells we compared the production of
hCD19+ B lineage cells in the BM of +T and –T mice. Flow cytometry analysis of
hCD19 expression on gated human (mCD45–hCD45+) cells showed that the percentage
of B lineage cells was almost double in +T as compared to –T xenograft mice (Figure
2.8C). A comparison of cell numbers in the BM showed that the number of B cells in +T
mice was 3-4 fold that observed in the –T animals. This increase was not due to a global
increase in hematopoiesis, but rather a selective increase in B cell production, since the
number of hCD19– cells in the BM was slightly less in +T as compared to –T xenograft
mice (Figure 2.8D). These data show that hTSLP produced in vivo in +T animals has a
functional effect on normal human B lineage cells that express low levels of CRLF2.

Figure 2.8D: Graphed are the average numbers of non-B lineage (hCD19–) and B lineage
(hCD19+) cells isolated from the BM (2 tibia plus 2 femurs) of –T and +T mice as
determined by hemocytometer count and flow cytometry (n=3 –T mice and n=5 +T mice).
Statistical significance was calculated using a 2-tailed, unpaired t-test  (**  p≤  0.01;;  ***  P  
≤0.001).

HTSLP in Xenograft Mice Induces MTOR-regulated Genes in Primary CRLF2 B-ALL
Our next question was whether hTSLP in the +T animals induces gene expression
profiles associated with pathway activation downstream of CRLF2-mediated signaling in
primary CRLF2 B-ALL cells. NSG mice for these studies were injected with +T stroma
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from transduction 1 and without a loading dose of stroma (Figure 2.9A). Serum levels of
hTSLP produced in these mice were detectable but below normal levels (4-10 pg/ml) and
therefore provide a sensitive test of hTSLP activity in +T mice.
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Figure 2.9 A-B: A) –T and +T NSG mice were transplanted with primary CRLF2 B-ALL
cells and injected weekly with 5X106 stromal cells. B) 9 weeks post-transplant, mice were
euthanized, BM was harvested and cells were stained with mCD45 and hCD19 to identify
human B-ALL cells. CRLF2 staining on gated hCD19+ cells is shown in bottom panels.

First, we evaluated the ability of NSG mice transplanted with HS27 stroma to
support engraftment of primary B-ALL cells. +T and –T NSG mice were transplanted
with primary cells (Figure 2.9B) aspirated from the BM of a Hispanic pediatric patient
with CRLF2 B-ALL. Animals were euthanized at 9 weeks when peripheral blood
chimerism reached 80%. BM was harvested and stained for mCD45 and human-specific
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markers (CRLF2 and CD19) to identify CRLF2 B-ALL cells (Figure 2.9B). Flow
cytometry analysis showed BM chimerism of human CRLF2 B-ALL cells was >90% in
BM from both +T and –T mice (Figure 2.9B). These data show that NSG mice injected
with –T and with +T stroma support engraftment of primary B-ALL cells.
Next we compared gene expression in primary CRLF2 B-ALL cells from +T and
–T mice using whole human genome oligo microarrays. Human CRLF2 B-ALL cells
were isolated from the BM of +T and –T mice by magnetic separation and whole genome
microarray was performed in triplicate using the Agilent platform. Differential gene
expression analysis identified 280 gene reporters that were upregulated and 281 gene
reporters that were downregulated at least 2 fold (Figure 2.9C). Microarray was validated
by quantitative RT-PCR (qRT-PCR) analysis of selected differentially expressed genes
(Table 5). Changes in gene expression by microarray and qRT-PCR were strongly
correlated as indicated by linear regression (Figure 2.9D).

Figure 2.9 C-D: C) Human hCD19+ B-ALL cells were isolated by magnetic separation and
analyzed using whole genome microarray to identify genes that are differentially regulated
in +T as compared to –T mice. Graphed are the number of Agilent gene reporters up or
down-regulated  (≥2  fold,  p≤  .05)  in  CRLF2  B-ALL cells from +T as compared to –T mice.
D) qRT-PCR validation of whole genome microarray. Regression analysis of fold changes
measured by microarray versus fold changes measured by qRT-PCR.
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GSEA (34, 35) was used to determine whether pathways induced by TSLP were
activated in CRLF2 B-ALL cells from +T as compared to –T xenograft mice. GSEA of
whole genome microarray data showed a strong enrichment (FDR q-value = 0.022) for
genes regulated downstream of mTOR activation in CRLF2 B-ALL cells from +T
animals as compared to –T animals (Figure 2.9E and Table 6).

Figure 2.9E: Gene Set Enrichment Analysis (GSEA) of whole genome microarray data
showed that CRLF2 B-ALL cells harvested from +T mice evidenced an increase in
expression of genes regulated downstream of mTOR signaling as compared to cells from
–T mice. The top half of the GSEA enrichment plot shows the enrichment score for each
gene and the bottom half shows the values of the ranking metric moving down the list of
the ranked genes.
IPA of microarray data was used to identify the most significantly regulated
canonical pathways in CRLF2 B-ALL cells from +T as compared to –T xenograft mice
(Figure 2.9F). IPA showed that the mTOR pathway, as well as associated pathways (EIF2
Signaling; Regulation of eIF4 and p70S6K Signaling) are among pathways significantly
regulated in CRLF2 B-ALL cells from +T as compared to –T mice.
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Figure 2.9F: Ingenuity Pathway Analysis (IPA) was performed based on gene reporters
that were significantly up or down-regulated  (1.7  fold,  p≤0.05).  Graphed  are  the  canonical  
pathways significantly enriched in samples taken from +T as compared to –T mice.

Taken together, GSEA and IPA analysis of gene expression data obtained from
CRLF2 B-ALL cells show that mTOR signaling is up-regulated in +T as compared to –T
xenograft mice. These data provide evidence that the hTSLP in +T mice, even when
present at low levels, acts on CRLF2 B-ALL cells to increase mTOR pathway activation
downstream of CRLF2. These data validate the use of +T/–T xenograft mice as a model
system for studies to understand the role of TSLP in normal B cell production and in the
development and progression of CRLF2 B-ALL.

TSLP Responsiveness is Reduced in Primary CRLF2 B-ALL Cells Expanded in
Xenografts Without HTSLP
TSLP is normally expressed by human BM stroma cells (see companion paper),
thus, TSLP-mediated CRLF2 signaling is likely to be present during the initiation and
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progression of CRLF2 B-ALL. PDX samples used for studies of CRLF2 B-ALL are
expanded in xenograft mice that lack the hTSLP required to activate CRLF2-mediated
signals. Thus, it is important to determine whether the production of CRLF2 B-ALL PDX
samples in xenograft mice that lack hTSLP can affect the subsequent response of these
cells to TSLP. To address this question, we compared the ex vivo TSLP responses of
CRLF2 B-ALL PDX samples generated in –T mice (–T PDX) to those generated in +T
mice (+T PDX) by evaluating downstream changes in gene expression (Figure 2.10A).

Figure 2.10A: TSLP responsiveness is reduced in primary CRLF2 B-ALL cells expanded
in xenografts without hTSLP. A) BM from the –T and +T patient-dervied xenografts
(PDX) generated from primary CRLF2 B-ALL cells as described in Figure 4 were
stimulated with or without TSLP ex vivo for 3 days. Cells were harvested and hCD19+
cells were isolated by magnetic separation and assessed using whole genome microarray.

BM harvested from the –T and +T PDX generated from primary CRLF2 B-ALL
cells (Figure 2.9) was cultured ex vivo with and without TSLP (Figure 2.10A). After 3
days of culture, cells were harvested and CRLF2 B-ALL cells were isolated by magnetic
separation for whole genome microarray using the Agilent platform. Differential gene
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expression analysis showed that 1632 gene reporters were up-regulated and 1754 gene
reporters were down-regulated  (fold  change  ≥  2.0;;  p≤0.05)  when  +T  PDX  were  
stimulated ex vivo with TSLP (Figure 7B). In contrast, the number of gene reporters
differentially regulated by TSLP was reduced by almost half (844 up-regulated and 914
down-regulated) in –T PDX (Figure 2.10B). These data suggest that primary CRLF2 BALL cells expanded in the absence of hTSLP have a reduced TSLP response with respect
to TSLP-regulated gene expression.
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Figure 2.10B-D: B) Graphed are the number of Agilent gene reporters that are up- or downregulated  (≥2  fold,  p≤  0.05)   in   –T PDX (white) and +T PDX (black) following ex vivo
stimulation by TSLP. C-D) Overlap (grey) between up- and down-regulated gene reporters
in –T PDX (white) or +T PDX (black) following ex vivo stimulation by TSLP

Our next question was whether the TSLP-regulated genes in –T PDX are the same
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as those in +T PDX. We examined the total gene reporters differentially regulated in
CRLF2 B-ALL cells, regardless of whether cells were expanded in +T or –T animals
(1814 total up-regulated and 1945 total down-regulated gene reporters) (Figure 2.10C-D).
Of the total gene reporters regulated by TSLP, approximately half were up- or downregulated in +T PDX, but not in –T PDX. Conversely, 10% of gene reporters were up or
down-related in –T PDX but not +T PDX. A little more than a third of gene reporters
were regulated by TSLP in both –T and +T PDX. While the gene sets up and downregulated by ex vivo TSLP stimulation were only partially overlapping, it is important to
note that no genes were oppositely regulated in +T and –T PDX samples.
Taken together these data suggest that primary CRLF2 B-ALL cells expanded in
xenograft mice without hTSLP show a reduced capacity to respond to TSLP as indicated
by a reduction in TSLP-induced changes in gene expression.

Discussion
Human-mouse xenografts provide a critical complement to other models in
understanding normal and malignant human B lymphopoiesis in context of the broad
background of human genetic variation. A limitation of these models is the lack of crossspecies activity observed for some cytokines. Here we show that mTSLP does not induce
the increases in STAT5 and PI3K/AKT/mTOR phosphorylation induced by hTSLP in
CRLF2 B-ALL cells (Figure 2.3). CRLF2 B-ALL cells express abundant IL-7Rα  and  
CRLF2 as compared to normal B cell precursors (Figure 2.2 and Figure S1-Appdx A)
and thus provide a sensitive test for mTSLP activity. These data establish that the classic
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mouse xenograft models do not provide cross-species activation of the human TSLP
receptor.
We developed a strategy to overcome the lack of mTSLP cross-species activity
while providing a +/– hTSLP (+T/–T) xenograft model system for studying the in vivo
role of TSLP in normal and malignant hematopoiesis. NSG mice were engineered to
express normal serum levels of hTSLP by intraperitoneal injection with stroma that had
been transduced to express hTSLP (+T mice) or transduced with a control vector (–T
mice). hTSLP produced in HS27 +T stroma induced STAT5 and PI3K/AKT/mTOR
pathway activation and exerted in vivo functional effects on primary CRLF2 B-ALL cells
(Figure 2.7) as well as normal B cell precursors (see Figure 2.8 and for a detailed analysis
see companion paper). Further, we found that primary CRLF2 B-ALL expanded in –T
mice showed a loss of TSLP responsiveness, as measured by TSLP-induced gene
regulation, when compared to cells from the same patient expanded in +T mice (Figure
2.10). The studies described here establish and validate a novel hTSLP+/– xenograft
model system while providing the first data on the in vivo impact of TSLP in normal
human B cell development and on primary CRLF2+ B-ALL cells.
Normal serum levels of hTSLP were achieved in our model, however, a novel
aspect of our model is the ability to modulate serum levels of hTSLP based on the timing
and number of injected stromal cells. The ability to vary hTSLP levels or to initiate
stromal cell injection (and TSLP production) at time points after transplantation offers
advantages for experimental design. A potential limitation of our model is that the hTSLP
is not produced directly from stroma in the BM. Although human BM stroma do produce
TSLP (see companion paper), the cells believed to produce the most hTSLP–a range of
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immune cells, smooth muscle cells, gut and skin epithelial cells (36)–reside outside the
BM. Thus, the major source of TSLP that acts on normal and malignant B cells in vivo in
patients may be produced outside the marrow as it is in our model. The ability to
modulate serum levels of TSLP is also biologically relevant because TSLP production is
increased by environmental factors such as pollutants and allergens and is up-regulated in
some autoimmune diseases and solid tumors (37) making this model relevant to studies in
these fields.
CRLF2 B-ALL is five times more prevalent in Hispanic and Native American
children than in others and is associated with poor outcome (26). CRLF2 B-ALL also
comprises more than 50% of B-ALL in children with Down syndrome (10, 17, 38).
Studies of the relationship between inherited genetic variation and susceptibility to ALL
provide some clues to the relationship of ALL to ethnicity (39). However, little is known
about cellular mechanisms that contribute to the initiation, progression and maintenance
of CRLF2 B-ALL or the biological factors that contribute to the health disparities
associated with this disease. Patient-derived xenograft (PDX) models are particularly
critical for health disparities diseases where inherited genetic variation or alterations such
as Down syndrome are likely to play a role in disease progression (40, 41). The primary
CRLF2 B-ALL sample used to develop the model described here was obtained from a
Hispanic pediatric patient. This PDX together with additional ones currently being
generated with the +T/–T xenograft model will allow us to study disease mechanisms 1)
in context of a genetic background associated with CRLF2 B-ALL health disparities and
2) in context of TSLP-CRLF2 mediated signals present in vivo in the patient.
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The model developed here provides an important new tool for understanding the
mechanisms of TSLP activity in normal and malignant B lymphopoiesis. It also provides
a preclinical model for identifying therapies to effectively treat CRLF2 B-ALL in an
environment that can induce the TSLP-mediated signals present in vivo in patients and in
context of the genetic background that leads to health disparities in this disease.
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CHAPTER THREE
TSLP EXERTS EFFECTS THAT ARE DISTINCT FROM IL-7 DURING
NORMAL B-CELL DEVELOPMENT

Abstract
The role of TSLP in human B cell development is largely unknown and its
function in context of IL-7 has not been studied. We found that TSLP can replace IL-7 in
providing a signal essential for in vitro production and proliferation of human
CD19+Pax-5+ B cell progenitors. To study the role of TSLP in human B cell
development, in the context of IL-7 stimulation, we developed a novel xenograft model.
Mouse IL-7 is active on human cells; however, this is not the case for TSLP. We took
advantage of this to develop a xenograft model system comprised of mice that provide
human TSLP (+T mice) and control mice that do not (–T mice). Using this model we
found that TSLP increases proliferation and up-regulates Mcl-1 in CD19–CD34+IL7R +
progenitors resulting in a 3-4-fold expansion of the CD34+ pro-B cell compartment in +T
as compared to –T mice. This expansion is maintained during subsequent stages of B cell
development, partially due to increased protection from apoptosis that occurs
independently of Bcl-2 family pro-survival proteins. TSLP stimulated in vitro
proliferation of pro-B cells, however, in vivo proliferation of B lineage precursors was
similar in +T and –T mice suggesting redundancy with IL-7. B cell subsets in normal
pediatric BM samples show progenitor ratios and Mcl-1 expression that mirrors that in
+T xenograft mice. These data provide evidence that TSLP function in human B
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lymphopoiesis includes both unique activities as well as activities redundant to those of
IL-7.
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Abbreviations
TSLP

Thymic Stromal Lymphopoietin

CRLF2

Cytokine Receptor-Like Factor 2

IL-

Interleukin 7 Receptor alpha chain

JAK

Janus Kinase

mTOR

Mammalian Target Of Rapamycin

PI3K

Phosphoinositide-3-Kinase

AKT

Protein Kinase B

PAX5

Paired Box 5

CD19

Cluster of Differentiation 19 (B-cell marker)

CD34

Cluster of Differentiation 34 (stem cell marker)

NSG

NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ)

BM

Bone Marrow

CB

Cord Blood (umbilical cord blood)

HSC

Hematopoietic Stem Cell

Mcl-1

Myeloid Cell Leukemia 1

Bcl-xl

Bcl-2 Like protein X

Bcl-2

B-cell Lymphoma 2

Flt-3

Fms-Like Tyrosine kinase 3

Ig

Immunoglobulin

7-AAD

7-Amino-Actinomycin D

BrdU

5-Bromo-2’-deoxyuridine
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Introduction
The roles of TSLP and IL-7 in mouse B lymphopoiesis include overlapping and
unique functions (1-5). In vitro studies of human B cell development show that TSLP
acts on fetal B cell precursors to induce proliferation (6), while IL-7 provides a signal
critical for the production and proliferation of non-fetal B lineage cells (7-9). The role of
TSLP in human B cell development beyond the fetal period has not been studied.
Furthermore, its role in context of IL-7 during normal in vivo B cell development is
unknown. Aberrant signaling in both the TSLP (10) and IL-7 (11) pathways is linked to B
cell acute lymphoblastic leukemia, underscoring the importance of understanding the role
of these cytokines in human B lymphopoiesis.
TSLP and IL-7 signal through distinct complexes comprised of the IL-7R and
homologous secondary chains (12). The secondary chain for the IL-7 receptor complex is
the common gamma chain ( c) (13), while the secondary chain of the TSLP receptor
complex is CRLF2 (TSLPR ) (14, 15). Both cytokines induce STAT5 activation,
however, TSLP acts through JAK2, while IL-7 effects are mediated through JAK3 (17).
Additionally, in human B lineage cells, TSLP induces the PI3K/AKT/mTOR pathway
activation (18), although available evidence suggests that this pathway is not activated by
IL-7 (19). Thus, TSLP and IL-7 exhibit both shared and distinct receptor components as
well as downstream signaling pathways.
IL-7R-mediated signals are likely to play different roles in mouse and human B
cell development. In mice, IL-7 activates the PI3K/AKT pathway in B lineage cells, but
this is not the case in humans (19). Furthermore, homologies in TSLP and in CRLF2,
between the two species are very low (~40% protein level identity) (20, 21). This
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contrasts with other cytokines and receptor components, including IL-7 and the IL-7R
which show ~70% homology between mouse and human. As a consequence, mouse
TSLP does not show cross-species activity on human cells (14) and companion
manuscript) while IL-7 does. This simultaneously highlights the importance of studying
B cell development in human systems, while identifying a challenge of doing so: mouse
TSLP does not activate the human TSLP receptor complex. Consequently, IL-7R
signaling in human B lineage cells generated in classic human-mouse xenografts, is
activated exclusively by mouse IL-7.
Here we use a novel human-mouse xenograft system that produces human TSLP,
together with human-only in vitro cultures and primary patient samples, to identify the
role of TSLP in human B cell development in vivo, in context of IL-7.

Materials and Methods
Human Samples
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance
with protocols approved by the Loma Linda University Institutional Review Board (IRB)
and with the Helsinki Declaration of 1975, as revised in 2008. CD34+ cells were isolated
by magnetic separation with CD34+ microbeads (Miltenyi Biotec, Auburn, CA) from
mononuclear cells. Detection of human TSLP production in BM stromal cells is
described in online supplementary methods.

Selective-Cytokine Co-cultures
Human-only co-cultures were as described (9). Briefly, CB CD34+ hematopoietic
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stem cells (HSC) cells were seeded on primary human BM stromal cells. Cultures were
maintained in medium supplemented with 5% human AB serum (Omega Scientific,
Tarzana, CA) lot tested to support human B cell production. All cultures, including
control, were supplemented with IL-3 and Flt-3 Ligand. For selective cytokine
stimulation, TSLP and/or IL-7 (R&D Systems Inc., Minneapolis, MN) were added. If
TSLP and/or IL-7 were not added, cultures were further supplemented with an antihuman neutralizing antibody to counter activity of endogenously produced TSLP and/or
IL-7. Cultures without specific neutralizing antibody (anti-IL-7 and/or anti-TSLP) were
supplemented with an isotype-matched control for the neutralizing antibody. Cultures
were maintained for three weeks, and then harvested. For BrdU incorporation, co-cultures
were labeled with 10 uM BrdU (Sigma-Aldrich, St. Louis, MO) for the final 24 hours of
culture.

Flow Cytometry
Cells were prepared for flow cytometry to detect surface antigens according to
manufacturer’s  protocols.  Details  of  intracellular  staining  and  specific  antibody  clones  
and conjugates are described in online supplemental methods. Flow cytometry analysis
was performed using a MACSQuant analyzer (Miltenyi Biotec, Inc. Auburn, CA) and
Flowjo data analysis software (TreeStar, Ashland, OR).

Statistical Analysis
Statistical analysis was performed using Students t test or one-way analysis of
variation (ANOVA) and data expressed as mean ± SEM. Statistical significance was
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defined as p<0.05.

Animal Studies
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory) under protocols approved by the Loma Linda University
Institutional Animal Care and Use Committee (IACUC). Mice were engineered by
intraperitoneal injection with stroma transduced to express human TSLP (+T mice) or
stroma transduced with control vector (–T mice) as described in the companion paper. +T
and –T mice were transplanted with 1"105 CD34+ cells by tail vein injection, after sublethal irradiation at 225 cGy. Mice were euthanized 5-7 weeks after transplantation and
tissues harvested and frozen for flow cytometry analysis.

Results
TSLP can Replace IL-7 in Supporting the In vitro Production and Proliferation of
Human CD19+Pax-5+ B cell Progenitors
To compare the effects of TSLP and IL-7 in early stages of human B cell
production, we developed a human-only culture model that provides selective cytokine
stimulation. Human CD34+ HSCs were cultured with primary human BM stromal cells
in media supplemented with human serum. Selective cytokine stimulation was achieved
by supplementing with combinations of exogenous IL-7 and/or TSLP and with
neutralizing antibodies to counter activity of endogenously produced IL-7 and TSLP in
cultures where cytokine is not added (Figure 3.1A). CB CD34+ HSCs were plated in
human-only selective cytokine cultures to compare the production of B cell progenitors
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under the influence of TSLP or IL-7 alone and in combination. Culture progeny were
harvested and stained for flow cytometry to identify CD19+PAX-5+ B lineage cells.
Control cultures that lacked TSLP or IL-7 showed little B cell production (Figure 3.1B).
In contrast, TSLP, IL-7, and TSLP+IL-7 cultures showed robust production of
CD19+PAX-5+ B lineage cells (Figure 3.1B). There was no significant difference in the
numbers of B lineage cells produced in cultures with TSLP as compared to cultures with
IL-7 (Figure 3.1C). Furthermore, there was no additive effect when cultures were
supplemented with both cytokines.

Figure 3.1 A-C: (A) Human-only cultures were produced by plating primary human CB
CD34+ cells on primary BM stromal cells. Selective cytokine stimulation was achieved by
supplementing cultures with exogenous IL-7 and/or TSLP or neutralizing antibodies to
TSLP (anti-T) or IL-7 (anti-7) as indicated. Cultures without a particular neutralizing
antibody were supplemented, as a control with non-specific isotype-matched antibodies
(ctrl Ig). All culture conditions included IL-3 and Flt-3 ligand, two cytokines that support
early lymphoid progenitors (35, 36). Cultures were maintained for three weeks, then
harvested and stained for flow cytometry. (B) Dot plots showing CD19 vs. Pax5 staining
in each culture condition are shown (representative of n=3 independent experiments).
PAX-5 fluorescence minus one (FMO) control is displayed in inset. (C) Graphed are the
relative numbers of CD19+ cells generated in vitro under indicated conditions at three
weeks (n=14).
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To determine if TSLP-induced proliferation contributes to the increased
production of human B cell precursors from CB HSCs, we compared BrdU incorporation
in cells generated under selective cytokine conditions (Figure 3.1D). Proliferation of B
cell precursors was significantly increased in TSLP cultures as compared to control
cultures without TSLP or IL-7 (Figure 3.1E). The percentage of BrdU+ cells in TSLP
cultures was similar to that observed for cultures with IL-7 or TSLP+IL-7. Collectively,
these data provide evidence that TSLP can replace IL-7 in providing signals that are
critical for the in vitro production and proliferation of CD19+PAX-5+ B cell precursors.
Further, the absence of additive effects observed in cultures with TSLP+IL-7 suggests
that TSLP and IL-7 do not act on different populations of cells but rather a common set
of B cell progenitors that can respond to either TSLP or IL-7.

Figure 3.1D-E: (D) Representative dot plots of CD19 vs BrdU staining in indicated
conditions. BrdU FMO control is displayed in the inset of the Ctrl dot plot. (E) Graphed is
the percent BrdU+ cells (mean± SEM) in the total CD19+ population generated under
indicated conditions at three weeks (n=8). Statistical analysis was performed using a oneway ANOVA, with Dunnett multiple comparisons post test, *p<0.05, **p<0.001.

In vivo Human B cell Production in Xenografts With and Without Human TSLP
The above data suggest that TSLP and IL-7 might provide redundant proliferative
signals but do not address the potential for differential effects at specific stages during in
vivo B cell development. We developed a novel xenograft model that allows us to study
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in vivo stage-specific development of human B lineage cells in the presence and absence
of TSLP. Unlike mouse IL-7, which can induce activation of the human IL-7R complex
(8, 22, 23), mouse TSLP does not (see (21) and companion manuscript). We took
advantage of this to develop a xenograft model system comprised of mice that provide
human TSLP (+T mice) and control mice that do not (–T mice) (Figure 3.2A). The
human TSLP in +T xenograft mice was active on normal human B lineage cells as
indicated by the lineage-specific increases in CD19+ B lineage cells generated from CB
CD34+ HSCs transplanted into +T as compared to –T mice (see chapter 2).

Figure 3.2A-B: Xenograft model of human B cell development. (A) Immune deficient NSG
mice were engineered by weekly intraperitoneal injection of stromal cells that were
transduced either with empty vector (–T mice) or to express human TSLP (+T mice) as
described in companion paper. CB CD34+ cells were injected by tail vein into –T and +T
mice. Five weeks later BM was harvested and stained for flow cytometry to detect antimouse CD45 (mCD45) and human-specific markers (B) to identify five developmentally
sequential B cell subsets in the BM of –T and +T mice. IL-7R+ progenitors, a population
of lymphoid-restricted multi-lineage progenitors (Su, unpublished data) were also
identified. Gated subsets are shown for –T mice.
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To distinguish in vivo, stage-specific effects of TSLP during human B cell
development, we compared progenitor and B lineage subsets produced in mice that
provide only IL-7 stimulation (–T mice) or both IL-7 and human TSLP stimulation (+T
mice). Xenograft mice were engineered to be –T and +T and transplanted with CB
CD34+ cells. Five weeks after transplantation, BM and spleens of mice were harvested
and stained for flow cytometry to identify developmental subsets of human B lineage
cells as well as IL-7R+ progenitors (Figure 3.2B). IL-7R+ progenitors are a population of
CD19–CD34+ progenitors that represent the earliest hematopoietic progenitors capable
of responding to TSLP and/or IL-7 based on their expression of IL-7R . We found that
all five B cell subsets, as well as IL-7R+ progenitors, were present in the BM of
xenograft mice irrespective of the presence of human TSLP (Figure 3.2C-D). Similarly,
spleens from –T and +T animals showed both immature and mature B cell subsets (data
not shown).
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Figure 3.2C-D: Gated subsets are shown for –T mice (C) and +T mice (D). The same gating
strategy was used to identify immature and mature B cells in the spleens of the –T and +T
mice.

TSLP Alters the Distribution of Human CD34+ Progenitors in the BM of
Xenograft Mice
In vitro studies of human fetal B cell development show that CD34+ progenitor
populations are responsive to TSLP (6). To determine whether TSLP effects on CD34+
populations are distinct from those of IL-7, we compared the distribution of CD34+ stem
cell and progenitor populations in the BM of –T and +T mice. Using gates shown in
Figure 9C, D, we determined the distribution of total CD34+ cells from –T and +T
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xenograft mice among three CD34+ subsets: HSCs/multi-lineage progenitors, IL-7R+
progenitors, and CD34+ pro-B cells. The progenitors produced with IL-7 stimulation
alone (–T xenograft mice) were distributed almost evenly between the three CD34+
subsets (Figure 3.3, left panel). In contrast, CD34+ progenitors produced with TSLP and
IL-7 showed a skewing toward CD34+ pro-B cells which made up more than 75% of the
entire CD34+ BM pool in + T mice (Figure 3.3, right panel). These data suggest that
rather than inducing a global expansion of B lineage cells by amplifying IL-7R signals in
a redundant fashion, TSLP exerts specific effects on CD34+ cells that are at least
partially distinct from those of IL-7 during the early stages of human B cell
differentiation from CD34+ CB HSCs.

Figure 3.3: Distribution of total human CD34+ BM cells from –T and +T xenograft mice
among three CD34+ subsets: HSCs/multi-lineage progenitors (CD19–CD34+IL-7R–), IL7R+ progenitors (IL-7R+), and CD34+ pro-B cells (CD19+CD34+), in BM of –T mice
and +T mice.

TSLP Expands the Earliest CD19+ B lineage Committed Cells at the Expense of
CD19–CD34+ cells that Express the IL-7R
To gain insights into populations targeted uniquely by TSLP, we compared the
absolute numbers of cells in developmental subsets produced in +T and –T mice. The
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number of cells in the HSCs and multi-lineage progenitor compartment was similar in
xenografts whether or not human TSLP was present. Surprisingly, in +T mice the number
of IL-7R + progenitors was reduced. This contrasts with subsequent stages of B cell
development, from CD34+ pro-B to mature B cells, where cell numbers were
significantly increased in +T as compared to –T mice (Figure 3.4, left panel). Similarly,
splenic numbers of immature and mature human B cells were increased in +T as
compared to –T mice (Figure 3.4, right panel).
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Figure 3.4: Absolute number of cells in each progenitor and B lineage subset in the BM
(left panel) and spleen (right panel) of –T (n= 3) and +T (n=5) xenograft mice. Statistical
analysis was performed using a one-tailed, t-test, *p<0.05, **p<0.01 and ***p<0.0001.
Error bars represent mean ± SEM.

Taken together, these data show that TSLP alters the distribution of CD34+
progenitor populations, increasing the CD34+ pro-B compartment at the expense of IL7R+ progenitors. These data suggest that TSLP exerts unique stage-specific effects
during early stages of B cell development. Furthermore, TSLP-induced increases in cell
numbers early in the B lineage extend through all stages of B cell development in the BM
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and spleen. These effects do no occur with IL-7 stimulation alone, suggesting that TSLP
plays a role that is distinct from IL-7 in expanding the B cell progenitor compartment
during in vivo human B lymphopoiesis.

TSLP-induced Expansion of CD34+ Pro-B cells is Maintained, but not Augmented at
Later Stages of In vivo B cell Development
Because cells in early developmental subsets give rise to cells that progress to
more mature stages of B cell development, the effect of TSLP on the most immature
progenitors will result in increased cell numbers at each subsequent stage of
development, independent of effects at more mature stages of development. To pinpoint
stage-specific effects of TSLP-induced expansion, we graphed the fold change in cell
numbers at each stage of B lineage development in +T mice relative to –T mice (Figure
3.5, left panel).

Figure 3.5: Graphed is the TSLP-induced fold change in the absolute number of progenitors
and B lineage cells in the BM (left panel) and spleen (right panel) of +T as compared to –
T xenograft mice. Subsets were gated as described in Figure 2. Statistical analysis was
performed using a one-way ANOVA, *p<0.05, **p<0.01 and ***p<0.001. Error bars
represent mean± SEM.
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The pool of HSC/multi-lineage progenitors was unchanged, but the IL-7R+
progenitor compartment was reduced in +T as compared to –T mice. Despite its reduced
size, the IL-7R+ progenitor population in +T xenograft mice gave rise to a CD34+ pro-B
compartment that was more than 4-fold increased when compared to –T mice. As B cell
development progressed, the ~4-fold increase was maintained until cells reached the
mature B cell stage, where numbers in +T xenograft mice were only 2 fold that observed
in –T mice. Similarly, the number of immature and mature splenic B cells (Figure 3.5,
right panel), as well as the splenic weight (data not shown) in +T animals was ~2 fold
that in –T xenograft mice. These data show that the overall increase in CD34+ pro-B cells
that we observed in +T mice is largely maintained, but not further increased as B cell
progenitors progress through each subsequent stage of development and migrate to the
spleen.

TSLP Increases Proliferation of IL-7R+ Progenitors but not CD19+ B lineage Cells
To determine the cellular mechanism(s) responsible for increased in vivo B
lineage production with TSLP stimulation, we first assessed proliferation based on Ki-67
expression in developmental subsets. The IL-7R+ progenitors generated in +T animals
showed increased Ki-67 expression (Figure 3.6, top panel). However, no differences in
proliferation were observed in any of the subsequent committed B cell subsets derived
from BM of the –T and +T mice.
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Figure 3.6: Top panel: Expression of Ki-67 proliferation antigen in developmentally
sequential progenitor B cell subsets in BM (left panel) and spleen (right panel). Bottom
panel: Progenitor and precursor IgM– subsets were further separated based on IL-7R , and
Ki-67 expression as indicated by MFI is graphed for each subset in the –T and +T
xenograft mice. Statistical analysis was performed using an unpaired one- tailed, t-test,
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Error bars represent mean ± SEM.
Data shown are from –T mice (n = 3) and +T mice (n=5).

The IL-7R chain is required for both IL-7 and TSLP-mediated signals. However,
typically only ~20-50% of human pro-B and pre-B cells express IL-7R (9) and it is
undetectable by the immature stage of B cell development (Milford, unpublished data).
To gain insights into the stage-specific roles of IL-7 and TSLP in the proliferation of B
lineage committed progenitors, we compared Ki-67 expression in IL-7R + and IL-7R –
subsets from –T and +T xenograft mice (Figure 3.6, bottom panel). In both +T and –T
mice, Ki-67 was significantly higher in the IL-7R + cells than in IL-7R – cells in the
pro-B and pre-B subsets.
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Taken together with data in Figures 8 and 9, these results suggest that TSLP
increases proliferation of IL-7R+ progenitors and promotes up-regulation of PAX-5
expression and differentiation to produce an expanded pool of differentiated
CD34+CD19+ pro-B cells. They also provide evidence that IL-7 and TSLP act in a
redundant manner to stimulate cycling of IL-7R + pro-B and pre-B cells.

TSLP Protects Developing CD19+ B lineage Cells from Apoptosis
Our next question was whether increased survival of B lineage cells might
contribute to the increased pool of B lineage cells that we observed in +T xenograft mice.
To address this question we evaluated apoptosis in IL-7R+ progenitors and B cell subsets
by flow cytometry. Graphed in Figure 3.7 are the percentage of cells in each subset that
were non-apoptotic as indicated by the absence of staining for the apoptotic markers,
Annexin V and 7-AAD. Notably, the percentage of non-apoptotic cells was significantly
higher in human pro-B, pre-B and immature B cells from +T as compared to –T mice.
Similar percentages of non-apoptotic cells were observed among IL-7R+ progenitors and
mature B cells (Figure 3.7) regardless of whether TSLP was present. Thus, during the
development of CD19+ B lineage cells, TSLP has a unique pro-survival function that is
not provided by IL-7.
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Figure 3.7: Graphed are the percentages of non-apoptotic cells (Annexin V– 7-AAD– cells)
in each subset from –T and +T mice. B) CD34+ progenitors along with B cell progenitor
and precursor subsets were gated into IL-7R – and IL-7R + fractions.

TSLP-mediated Protection from Apoptosis is Independent of Bcl-2 Family Pro-survival
Protein Expression
To gain insights into the role of TSLP and IL-7 in the survival of developing B
lineage cells and the contribution of Bcl-2 family pro-survival proteins in this process, we
compared the expression of Bcl-2, Bcl-xL and Mcl-1 in IL-7R– and IL-7R+ cells within
early progenitor and B cell precursors subsets. Expression of pro-survival molecules was
first evaluated in B lineage cells produced in –T mice under the influence of IL-7 alone.
With only IL-7, Bcl-2, Bcl-xL, and Mcl-1 were significantly increased in IL-7R+ as
compared to IL-7R– cells in almost all subsets examined, from the most primitive IL7R+ progenitors through the pre-B cell stage (Figure 3.8 top panel). The exception was
the marked absence of Mcl-1 up-regulation in IL-7R+ progenitors as compared to the
HSC/multi-lineage progenitor population (CD19–CD34+IL-7R– cells).
Next, we evaluated the expression of Bcl-2 family proteins during human B cell
development in +T mice that provide TSLP in context of IL-7. When we compared IL7R– and IL-7R+ subsets from +T mice the pattern of Bcl-2, Bcl-xL, and Mcl-1
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expression was almost identical to that observed in –T animals (Figure 3.8 top panel and
Figure 3.8 bottom panel). However, in +T mice, we found that Mcl-1 expression was
increased in the IL-7R+ progenitors as compared to their IL-7R– counterparts, which
showed the same low level of Mcl-1 expression observed in all CD19–CD34+ cells in –T
animals (bottom panel, far right). These data show that all three Bcl-2 family pro-survival
proteins are up-regulated in human pro-B and pre-B cells that are IL-7R+ as compared to
IL-7R– and that this up-regulation occurs whether or not TSLP is present. In contrast,
TSLP exerts effects distinct from IL-7 to up-regulate Mcl-1 in human IL-7R+
progenitors.
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Figure 3.8: Top panel: Graphed are the median fluorescence intensities (MFI) of (B) Bcl2, (C) Bcl-xL and (D) Mcl-1 in –T mice. Data are from n = 6 or 7 mice per group. Statistical
analysis was performed using one-tailed, t-test, *p<0.05, **p<0.01 and ***p<0.001. Error
bars represent mean ± SEM. Bottom panel: Graphed are the median fluorescence intensities
(MFI) of (E) Bcl-2, (F) Bcl-xL and (G) Mcl-1 in +T mice. Data are from n = 6 or 7 mice
per group. Statistical analysis was performed using one-tailed, t-test, *p<0.05, **p<0.01
and ***p<0.001. Error bars represent mean ± SEM.

Overall, our data show that TSLP targets IL-7R+ progenitors in a manner distinct
from IL-7 to increase proliferation, up-regulate expression of the Mcl-1 pro-survival
protein, and promote differentiation of an expanded CD34+ pro-B cell pool. This
population is expanded and/or maintained in subsequent stages of development by TSLP
via unidentified mechanism(s) that are independent of Bcl-2 family pro-survival protein
expression.
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TSLP is Expressed by Human BM Stromal Cells
Our next step was to investigate whether the TSLP effects we observed in +T
xenograft mice are consistent with normal in vivo human B cell development. To
determine if BM stroma provide an in vivo source of TSLP to support human B cell
production, we isolated RNA from the stromal cells of normal BM donors and performed
RT-PCR. We evaluated TSLP expression, and IL-7 for comparison. Figure 3.9A shows
that BM stromal cells express transcripts for TSLP, as well as IL-7. To verify that TSLP
transcripts result in protein production, supernatant taken from cultured BM stromal cells
was evaluated by enzyme-linked immunosorbant assay (ELISA). TSLP, as well as IL-7
proteins were detected in culture supernatants (Figure 3.9B). These data demonstrate that
human BM stromal cells produce TSLP, in addition to IL-7, and thus provide a source for
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Figure 3.9: In vivo human B cell production mirrors xenograft mice with human TSLP. (A)
RT-PCR was used to detect TSLP, IL-7 or beta-2 microglobulin (#2M, control) transcripts
in primary human BM stromal cells from different human donors – pediatric (BM#1 and
BM #2) and adult (BM #3) or water as a negative control. (B) Supernatant from confluent
BM stromal cell cultures were assessed by ELISA for TSLP and IL-7 protein production.
Dashed lines (---) represent ELISA threshold of detection.
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In vivo B cell Production in Patients Shows Progenitor Ratios and Mcl-1 Expression
that Mirrors Human B cell Production in Xenograft Mice with TSLP
In +T mice, the CD34+ pro-B compartment is expanded at the expense of IL-7R+
progenitors giving a dramatically different distribution of CD34+ subsets than in –T
mice. To determine whether this altered distribution reflects normal human B cell
development, we compared the ratio of CD19+CD34+ pro-B cells to IL-7R+ progenitors
in BM from pediatric patients to that in xenograft mice. Xenograft or patient BM was
stained for flow cytometry to detect human specific B lineage and progenitor markers.
Total living CD34+ cells were gated into CD19+CD34+ pro-B and IL-7R+ progenitors
(Figure 3.10, left panel). In pediatric BM, the ratio of CD19+CD34+ pro-B to IL-7R+
progenitors was 7.2 to 1 (Figure 3.10, right panel). This was similar to that observed in
+T xenograft mice (9.1 to 1) but significantly higher than in –T mice (1.5 to 1) (Figure
3.10, right panel).

Figure 3.10: Left panel: Plotted are the gated living total CD34+ cells from the BM of –T
xenograft, +T xenograft and normal pediatric patients. Right panel: Graphed is the ratio
of CD34+ pro-B cells to IL-7R+ progenitors among BM-derived total CD34+ cells from –
T xenograft mice (n=3), +T xenograft mice (n=5) and from normal pediatric patient
samples (n=10). CD34+ progenitors and early B cell subsets from the BM of normal
pediatric patients were gated into IL-7R – and IL-7R + fractions.
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We wanted to know whether the pattern of Bcl-2 family protein expression that
implicates IL-7R -mediated signals in the survival of developing B cells in xenograft
mice was also present in vivo in patient samples. Normal pediatric BM samples were
analyzed for Bcl-2 family protein expression by flow cytometry. The pattern of upregulated Bcl-2 and Mcl-1 in IL-7R+ subsets of pro-B and pre-B cells that we observed
in pediatric patient samples was similar to that observed in –T and +T xenograft mice
(Figure 3.11, left panel). Bcl-xL showed up-regulation in some, but not all IL-7R+
subsets (Figure 3.11, middle panel). Notably, in normal pediatric BM we found that Mcl1 was up-regulated in IL-7R+ progenitors as compared to HSC/multi-lineage progenitor
population (CD19–CD34+IL-7R– cells) (Figure 3.11, right panel) ––a feature unique to
B cell production in xenograft mice with TSLP. Taken together these data show that
normal pediatric B cell development shares features unique to xenograft mice with
human TSLP, namely a high ratio of CD34+ pro-B cells to IL-7R+ progenitors and upregulated Mcl-1 in IL-7R+ progenitors.

Figure 3.11: Left panel: Graphed are MFI of Bcl-2 (n=6); middle panel: Bcl-xL (n=10) and
right panel: Mcl-1 (n=9) in the IL-7R –/+ fractions of normal pediatric BM. Statistical
analysis was performed using two-tail, t-test, *p<0.05, **p<0.01 and ***p<0.001. Error
bars represent mean ± SEM.
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Discussion
Here we use a novel xenograft model system that allows us to study human B cell
development in vivo with and without TSLP and in context of IL-7 stimulation. Using
this model we show that TSLP uniquely targets CD19–CD34+ progenitors expressing the
IL-7R , inducing increased proliferation and Mcl-1 expression that is not observed
during in vivo human B cell development with IL-7 stimulation alone. Rather than
expanding the IL-7R+ progenitor population, these activities result in a dramatically
expanded CD34+CD19+ pro-B cell compartment suggesting that TSLP promotes the
differentiation of newly produced cells into the B lineage. This is supported by in vitro
experiments showing that TSLP promotes the production of CD19+Pax-5+ B lineage
cells from CB CD34+ progenitors. In pediatric BM samples we observed a 7:1 ratio of
CD34+ pro-B cells to IL-7R+ progenitors as well as up-regulated Mcl-1 in IL-7R+
progenitors. This mirrors what we observed in +T mice suggesting that the effects
produced by TSLP occur during normal in vivo B cell development in children.
Genetic alterations leading to activation or overexpression of the TSLP receptor
component, CRLF2, are linked to malignant transformation and high-risk B cell
precursor acute lymphoblastic leukemia (26, 27). This suggests a role for TSLP receptor
activation in the proliferation and/or survival of early human B lineage cells. Our data
show that TSLP is similar to IL-7 in that it stimulates the in vitro proliferation of normal
B cell precursors derived from CB CD34+ cells (Figure 8). Our data in normal B cell
precursors are consistent with previous reports (28, 29) suggesting a role for TSLPCRLF2 mediated signals in the proliferation of B-ALL cells. Our xenograft studies also
suggest a role for TSLP, distinct from that of IL-7 and independent from Bcl-2 family
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pro-survival molecules, in protecting developing CD19+ B lineage cells from death. It
should be noted that the up-regulation of Bcl-2 family pro-survival proteins that we
observed in IL-7R+ subsets of developing B lineage cells, with or without TSLP, could
also be a function of TSLP that is redundant to IL-7 and therefore indistinguishable in our
model.
Our studies suggest TSLP has roles that are both distinct and redundant to IL-7 in
human B cell development. It is important to note that our studies were performed using
postnatal sources that most closely reflect B cell development in the pediatric population.
This is important because murine studies suggest that the role of IL-7 is less critical (30)
and TSLP may play a larger role (2, 3) at early points in life, although the latter remains
controversial (31). Thus, it will be important to evaluate the role of TSLP during adult B
cell development using the model that we have developed here.
Understanding the potential contribution of TSLP to B cell production throughout
life is important because a range of factors influence TSLP levels and potentially B cell
production. TSLP expression is increased by environmental pollutants (32-34) and is
elevated in inflammatory diseases including asthma, atopic dermatitis and arthritis (3234). Our data show that increases in circulating TSLP increases the proliferation and
reduces the numbers of IL-7R+ progenitors. This raises the question of whether high
levels of circulating TSLP could exhaust the lymphoid progenitor population. If so, this
has the potential for long-term impact on the production of adaptive immune cells in
people with chronically elevated TSLP.
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CHAPTER FOUR
TSLP REGULATES CELL DEATH AND CELL SURVIVAL MECHANISMS
AND INDUCES APOPTOSIS IN CRLF2 B-ALL CELLS

Abstract
Pediatric CRLF2 B-ALL is a high-risk form of leukemia that is associated with
poor patient survival outcomes. CRLF2 B-ALL is five (5) times more prevalent in
Hispanic children and is associated with a higher rate of relapse. Genetic defects in the
CRLF2 gene have led to the overexpression of the CRLF2 protein- a receptor component
for TSLP- on the surface of B-ALL cells. The disease mechanisms of CRLF2 B-ALL are
unclear; more importantly, the role of TSLP in the maintenance and progression of
CRLF2 B-ALL is unknown. TSLP induces proliferation of normal human B-cell
precursors and is produced by human bone marrow stromal cells, suggesting that it is
present in the BM microenvironment where leukemia develops. Therefore we
hypothesized that TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or
survival of leukemia cells via regulation of genes downstream of CRLF2 pathway
activation. Using the novel hTSLP+/hTSLP- xenograft model, we demonstrated that
TSLP up-regulates cell death and survival genes and biological pathways and induces
apoptosis in CRLF2 B-ALL cells in vivo and in vitro. Further, TSLP transiently increases
Bcl-2 pro-survival family member Mcl-1, suggesting that TSLP-induced cell death and
survival mechanisms are mediated by Mcl-1. The studies described in this chapter
provide evidence that TSLP plays a role in regulating the survival mechanisms of CRLF2
B-ALL and has future implications for the treatment of this disease.
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Abbreviations
TSLP

Thymic Stromal Lymhopoieitin

TSLPR

Thymic Stromal Lymhopoieitin receptor beta (or CRLF2)

CRLF2

Cytokine Receptor-Like Factor 2 (or TSLPR )

IL-7R

Interleukin 7 Receptor alpha

CD34

Cluster of Differentiation 34 (stem cell marker)

CRLF2 B-ALL

CRLF2 B-cell Acute Lymphoblastic Leukemia

JAK

Janus Kinase

STAT

Signal Transducers and Activators of Transcription

BaF3

Murine Pro-B cell line

PI3K

Phosphoinositide-3-Kinase

AKT

Protein Kinase B

mTOR

Mammalian Target Of Rapamycin

ERK

Extracellular signal-Regulated Kinases

MAPK

Mitogen-Activated Protein Kinase

hTSLP

Human TSLP

Bcl-2

B-cell Lymphoma 2

Bcl-xl

Bcl-2 Like protein X

Mcl-1

Myeloid Cell Leukemia 1

BM

Bone Marrow

PB

Peripheral Blood

7-AAD

7-Amino-Actinomycin D

PDX

Patient Derived Xenograft
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NSG

NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ)

CD45

Cluster of Differentiation 45 (leukocyte marker)

CD19

Cluster of Differentiation 19 (B-cell marker)

CD10

Cluster of Differentiation 10 (B-cell marker)

DGA

Discriminatory Gene Analysis

GSEA

Gene Set Enrichment

IPA

Ingenuity Pathway Analysis

EIF2

Eukaryotic Initiation Factor 2

ROS

Reactive Oxygen Species

NADH

Nicotinamide Adenine Dinucleotide

ER

Endoplasmic Reticulum
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Introduction
TSLP, initially detected in the conditioned medium of epithelial cells that are
found in the thymic medulla is produced in the lung, bronchial tree, intestine and skin [1,
2]. TSLP performs physiological roles in inflammation, allergic reactions, helminthic
infections and the development of various hematopoietic cells [3-5]. High levels of TSLP
have been linked to asthma, allergy, atopic dermatitis and autoimmune diseases [6].
TSLP performs its functions by signaling through the TSLP receptor, which comprises of
the IL-7R and TSLPR [7]. Using microarray, Lu, et al demonstrated that different cells
express varying levels of TSLPR . For example, myeloid dendritic cells express high
levels of TSLPR ; CD34+ human hematopoietic progenitor-derived mast cells express
low levels of TSLPR; and B-cells show undetected levels of TSLPR [8]. Surprisingly,
the low levels of TSLPR expressed on B-cells are sufficient for TSLP to bind and
induce proliferation of B-cell precursors ([7]; chapter 2 and 3). However, more recently,
several groups have shown that genetic defects in the CRFL2 (another name for
TSLPR ) gene led to overexpression of the CRLF2 protein on the surface of leukemia
cells [9-11]. These leukemia cells are a high-risk subset of B-cell Acute lymphoblastic
leukemia referred to as CRLF2 B-ALL. CRLF2 B-ALL patients experience a 65%
relapse rate and have an overall poor survival outcome [12].
Studies conducted by Children Oncology Groups (COGs) have been directed
towards genomic profiling and risk stratification in order to identify high-risk patients
such as CRLF2 B-ALL patients [13, 14]. Additional studies have been conducted to
assess CRLF2 B-ALL patient response to current treatment regimens and to determine
therapeutic outcome, but very little is known about the mechanisms that contribute to the
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initiation, progression and maintenance of the disease [15, 16]. Recent molecular studies
have shown that in some cases overexpression of CRLF2 is associated with activating
mutations in JAK2, a kinase which acts downstream of TSLP-CRLF2 interactions [17].
The CRLF2 gene defects and JAK2 activating mutations have been shown to cooperate in
promoting constitutive dimerization, constitutive JAK-STAT activation and cytokine
independent growth in the murine BaF3 cellular model system [10, 11].
These data have led others to the conclusion that over-expression of CRLF2 and
activating JAK mutations are the major contributors to this disease and the current dogma
is that CRLF2 B-ALL cells do not require TSLP-induced signals for survival and
proliferation due to constitutive activation of the JAK-STAT pathway. Therefore studies
to evaluate the efficacy of treatments for CRLF2 B-ALL are conducted in context of
JAK-mutations and without TSLP-induced CRLF2 signals [18]. However, all JAK
mutations are not activating and 30% of CRLF2 B-ALL patients have no mutations in
JAKs [17]. Furthermore, our lab and others have shown that TSLP increases the
phosphorylation of STAT5, S6 and ERK which provided evidence of activation of the
JAK-STAT, PI3K/AKT/mTOR and ERK pathways and more importantly in cells with
JAK mutations [19]. Thus, the contributions of TSLP (the ligand that stimulates CRLF2
signaling) to the maintenance/progression of CRLF2 B-ALL and the cellular and
molecular mediators involved remain to be elucidated.
Here we use a novel hTSLP+/hTSLP- human-mouse xenograft in vivo system, in
vitro studies and gene arrays to show that TSLP regulates cell death and survival
mechanisms and induces apoptosis in CRLF2 B-ALL cells, in spite of the up-regulation
of Bcl-2 family member Mcl-1.
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Materials and Methods
Mice
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory). Mice were housed under pathogen-free conditions in the Loma
Linda University Animal Care Facility and studies were conducted in accordance with
Loma Linda University Institutional Animal Care and Use Committee (IACUC)
approved protocols. Leukemia cell lines and primary cells (CRLF2 B-ALL and nonCRLF2 B-ALL primary cells) were expanded in NSG mice for 9-11 weeks. Animals
were euthanized at end point by CO2 asphyxiation. Animal tissues including bone
marrow (BM), spleen and peripheral blood (PB) were harvested and processed. BM cells
were collected by removing long bones (femora, humeri) from mice and flushing the
bones with a PBS solution using a syringe.

In vivo Apoptosis Assay
hTSLP+/hTSLP- mice were produced by injecting NSG mice weekly with 5X106
HS27 stromal cells that were transduced with a lentiviral vector that expresses human
TSLP (hTSLP+) or an empty vector (hTSLP-). Mice were then transplanted with 510X106 human CRLF2 B-ALL cell lines or primary cells. Prior to euthanasia, TSLP
levels in animal sera were measured weekly by ELISA to monitor the levels of human
TSLP in hTSLP+ mice and hTSLP– mice. CRLF2 B-ALL cells expanded in hTSLP+ or
hTSLP- mice were harvested from tissues (BM, spleen and PB) and stained for flow
cytometry analysis with the following markers: mouse CD45 to identify mouse
leukocytes; human CD19 to identify human B-ALL cells; TSLPR (CRLF2) to identify
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CRLF2+ B-ALL cells as a measure of bone marrow disease; and Annexin V and/or 7AAD to detect cells that are in early or late stages of apoptosis.

Whole-genome Microarray
Primary CRLF2 B-ALL cells were harvested from the BM of hTSLP+ and
hTSLP- mice and hCD19+ B-ALL cells were isolated by magnetic separation using the
MACS cell separation kit (Miltenyi Biotec). After separation, cells were rapidly frozen
and shipped to Miltenyi Biotec for sample preparation, whole genome microarray, and
discriminatory gene analysis (Miltenyi Genomic Services, Germany).

In vitro Apoptosis Assay
CRLF2 B-ALL cell lines or primary cells were maintained in RPMI 1640 medium
supplemented with penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 20% fetal
bovine serum (FBS). Cells were cultured with the above media in the presence or absence
of TSLP for 3, 6 or 9 days, then harvested and stained with Annexin V and 7-AAD to
identify cells in early stages (Annexin V+, 7-AAD–) or late stages (Annexin V+, 7AAD+) of apoptosis for flow cytometry analysis. This experiment was repeated with IL7. Cell cultures included neutralizing antibodies to TSLP or IL-7 and nonspecific isotype
matched control antibodies.

In vitro Pro-survival Protein Assay
CRLF2 B-ALL cells were cultured in cell culture media with or without TSLP
along with the appropriate controls (described above) for 3, 6 or 9 days. Cells were
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harvested and assessed for the expression of Bcl-2 family members (anti-apoptotic
proteins: Bcl-2, Bcl-xl and Mcl-1) using a caltag fixation and permeabilization
intracellular flow cytometry protocol (Life Technologies).

Results
TSLP Induces Apoptosis in CRLF2 B-ALL Cells In vivo
The development of the novel hTSLP+/hTSLP- xenograft model described in
chapter 2 provided an in vivo tool that can be used to study the role of TSLP in normal
human B-cells (see chapter 3) and most importantly the role of TSLP in CRLF2 B-ALL.
Using the hTSLP+/hTSLP- model, data described in chapters 2 and 3 showed that TSLP
induces proliferation and survival of normal B-cells and induces activation of the mTOR
pathway and its related genes in primary CRLF2 B-ALL cells. These data provided
evidence that 1) the hTSLP+/hTSLP- model provides the human TSLP-CRLF2
interactions that are required to activate normal human B-cells and human CRLF2 BALL cells in vivo and 2) hTSLP induces cell proliferation and cell survival signals in
normal B-cells. The results obtained from the studies that evaluated the effects of TSLP
on normal B-cells supports our hypothesis that TSLP induces proliferation and survival in
these cells, however, the effects of TSLP on human CRLF2 B-ALL cells remain to be
elucidated. Therefore, using the novel hTSLP+/hTSLP- xenograft model, we evaluated
the effects of TSLP on CRLF2 B-ALL cells by testing the overarching hypothesis that
TSLP contributes to CRLF2 B-ALL by increasing proliferation and/or survival of
leukemia cells via regulation of genes downstream of CRLF2 pathway activation.
To test this hypothesis, first we evaluated the effects of TSLP on CRLF2 B-ALL
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cells in vivo by creating patient-derived xenografts (PDXs), administering varying levels
of TSLP and assessing leukemia cell viability. PDXs were developed by transplanting
NSG mice with primary CRLF2 B-ALL cells via tail vein injections and allowing the
cells to expand in vivo for 9-11 weeks. Prior to or on the day of leukemia cell
transplantation, NSG mice were injected with either low levels of TSLP (<10 pg/ml) or
higher levels of TSLP (~20 pg/ml) and leukemic cell BM chimerism was determined
using mouse and human cell markers. To accomplish this, BM cells were harvested from
mice at euthanasia, cells were co-stained with mouse CD45, human CD19 and human
CRLF2 to determine engraftment of human leukemia cells; and Annexin V to identify
apoptotic cells.
When low levels of TSLP were administered, our data showed that ~88% of cells in
the BM of +T mice were CRLF2 B-ALL cells while 83% of cells in the BM of –T mice
were CRLF2 B-ALL cells (Figure 4.1, top panel). Engrafted cells were mCD45–
hCD19+hCRLF2+. The percent of cells engrafted is a measure of BM disease, therefore
based on this definition, the data suggests that there is no difference in BM disease in +T
mouse compared to –T mouse.
To determine the effect of TSLP on the viability of engrafted cells, BM cells were
also stained with Annexin V and 7-AAD. Cells were first gated using mCD45, hCD19
and hCRLF2 to determine the percent of hCD19+ cells (Figure 4.1, top panel) and the
percent CRLF2 B-ALL cells (Figure 4.1, middle panel). The engrafted cells were gated to
show Annexin V+ cells. The dot plot showed that the percent of living hCD19+ cells in
the BM of +T mouse was half as much as the percent of hCD19+ cells in the BM of –T
mouse (Figure 4.1, bottom panel). Our data showed no observable differences in BM
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engraftment in +T and -T mice, however, there is a higher percent of apoptotic leukemic
cells in the BM of the +T mouse compared to -T mouse.

Figure 4.1: Primary CRLF2 B-ALL cells were injected into –T and +T mice and animals
were euthanized 9 weeks post transplant, BM was harvested and cells were co-stained with
mCD45, hCD19, hCRLF2 and Annexin V. hCD19+ cells were sub-gated to determine the
percent of CRLF2+ and Annexin V+ cells.

When higher levels of TSLP was administered, our data showed that for primary
CRLF2 B-ALL#1, 2.35 % of cells in the BM of +T mice were CRLF2 B-ALL cells
compared 28.1 % of cells in the BM of –T mice- n=2 (Figure 4.2, top panel). For primary
CRLF2 B-ALL#2, 0.2% of cells in the BM of +T mice were CRLF2 B-ALL cells,
compared to 95% of cells in the BM of –T mice- n=2-10(Figure 4.2, bottom panel).
Therefore at low levels of TSLP there was no observable difference in BM engraftment,
while at higher levels of TSLP, there was a dramatic decrease in the percent of CRLF2 B-
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ALL cells engrafted in the BM of +T mice. Data obtained from secondary and tertiary
CRLF2 B-ALL PDX showed similar results, irrespective of the source of the cells for the
2o and 3o transplants, i.e. irrespective of whether BM or Spleen cells were used. The data
suggests that at higher doses (~20 pg/ml – reported physiological levels), TSLP exerts an
effect on CRLF2 B-ALL BM disease- that is, TSLP specifically reduces the tumor
burden in mice.

Figure 4.2: Primary CRLF2 B-ALL cells from two different patients (B-ALL#1 and BALL#2) were injected into –T and +T mice and animals were euthanized 9-11 weeks post
transplant, BM was harvested and cells were co-stained with mCD45, hCD19 and hCRLF2.
Gated hCD19+ cells is a measure of BM disease.

Results from staining with apoptotic markers and gating cells as described above
in figure 4.1 showed that the CRLF2 B-ALL cells engrafted in +T mice and –T mice
when during higher levels of TSLP, were Annexin V–. Virtually all cells engrafted in the
BM of +T as well as –T mice were viable living cells.
In summary, our data showed that when low levels of TSLP is present in +T mice,
there’s  a  higher  percentage  of  CRLF2  B-ALL cells in the BM, but most of these cells
undergo apoptosis. However, when higher levels of TSLP are present in the +T mice,
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there is low to no engraftment of CRLF2 B-ALL cells and these engrafted cells are
viable. Taken together, these data suggest that increasing the levels of TSLP produces a
differential effect on CRLF2 B-ALL cells in vivo. Further, this differential effect of TSLP
is demonstrated by its induction of apoptosis in leukemia cells at lower levels and the
absence of leukemia cells at higher levels. Moreover, these results were
observed/maintained over subsequent transplants and were unique to the +T condition
irrespective of the source of cells.

TSLP Activates Cell Death and Survival Pathways and Cellular Functions in CRLF2
B-ALL Cells In vivo
In order to gain a better understanding of how TSLP regulates the cellular
functions we observed in CRLF2 B-ALL cells in vivo, we performed whole genome
microarray studies to identify genes that are up-regulated by TSLP, the biological
pathways that are implicated by these genes, and the molecular and cellular functions that
ensue as a result of the up-regulation of these genes and pathways. To accomplish this,
primary CRLF2 B-ALL cells were expanded in +T and -T mice for 9 weeks, BM was
harvested, CD19+ leukemia cells were isolated by magnetic separation and the cells were
shipped to Miltenyi Biotec (Miltenyi Genomic Services) for whole genome microarray
and discriminatory gene analysis (DGA). GSEA and IPA were performed using whole
genome microarray data files. Results from GSEA analysis showed that TSLP induced
activation of the mTOR pathway and its related genes in primary CRLF2 B-ALL cells
that were expanded in +T compared to –T mice (chapter 2 and Table 6). Studies have
shown that the mTOR pathway functions to regulate cell growth and survival [20]. IPA
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results provided additional evidence that the mTOR pathway was up-regulated by TSLP
in these cells. In addition to the mTOR pathway, the IPA results also showed that a list of
other canonical pathways were significantly up-regulated (compared to mTOR) by TSLP
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in CRLF2 B-ALL cells (Figure 4.3).

Figure 4.3: Ingenuity Pathway Analysis (IPA) was performed based on gene reporters that
were significantly up-regulated (2.0 fold,   p≤0.05).   Graphed   are   the   canonical   pathways  
significantly enriched in samples taken from +T as compared to –T mice.

The data showed that in addition to the mTOR pathway, mitochondrial dysfunction
(most significantly up-regulated) followed by EIF2 signaling and other cell metabolism
pathways were also up-regulated by TSLP (Figure 4.3). Studies have shown that
mitochondrial dysfunction is linked to the generation of reactive oxygen species (ROS) in
cells; it affects processes such as lipid metabolism; and is implicated in the intrinsic
(mitochondrial) apoptosis pathway [21-23]. EIF2 signaling has been shown to regulate
protein translation in response to cellular stress that is induced by viral infection, heme
deprivation, oxidative stress, ER stress, nutrient deprivation, heat shock, proteasome
inhibition and UV irradiation [24]. Other studies have also shown that EIF2 can activate
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both pro-apoptotic and pro-survival cellular pathways [25, 26]. Alternatively, mTOR
signaling has been shown to induce cellular growth and proliferation [27]. Careful
investigation of the top 10 pathways listed showed that mitochondrial dysfunction, EIF2
signaling, MAPK signaling in influenza are involved in cell death/cell stress mechanisms;
while eIF4 and p70S6K signaling, glycolysis, gluconeogenesis, TGF , PRPP
Biosynthesis, NADH repair and HMGB1 signaling are involved in cell survival
mechanisms.
Additional IPA analyses revealed that the top associated network function that was
up-regulated in the +T CRLF2 B-ALL sample but not in the –T sample was the network
responsible for cellular assembly, cellular organization, cellular death and survival and
cellular morphology. Most importantly, the top cellular and molecular function of the cell
that was up-regulated by TSLP is cell death and survival, with a total of 34 genes
involved in these processes (Table 1). Cell death and survival was followed by other
cellular functions including free radical scavenging, lipid metabolism, molecular
transport and small molecule biochemistry. In summary, the biological pathways upregulated by TSLP reflect the involvement of cell death, cell stress and cell survival
mechanisms. This data is further supported by the results that showed that the top cellular
and molecular function of the cell that was regulated by TSLP was cell death and
survival. Taken together, these data suggest that both cell death and cell survival
functions as well as their downstream pathways are involved in TSLP-CRLF2 signaling
in CRLF2 B-ALL cells that were expanded in the +T mouse.
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Table 1: List of cellular and molecular functions that are up-regulated by TSLP in primary
CRLF2 B-ALL cells expanded in +T mice compared to –T mice. The number of molecules
refers to the number of genes that are up-regulated by TSLP and contribute to the respective
cellular/molecular functions listed to the left.

TSLP Induces Apoptosis in CRLF2 B-ALL Cells In vitro
The molecular data obtained from the IPA of CRLF2 B-ALL +T and –T PDXs
suggested that TSLP may play a role in regulating cell death and cell survival
mechanisms and further substantiated the apoptotic effects of TSLP on CRLF2 B-ALL
cells that was observed in vivo. Therefore to further elucidate the mechanisms by which
TSLP regulates cell death and survival, we evaluated the effects of TSLP on CRLF2 BALL cells in vitro. To accomplish this, we cultured human CRLF2 B-ALL cell lines with
or without TSLP for 3, 6 or 9 days and assessed cell death by staining cells with apoptotic
markers- Annexin V and 7-AAD. Cells were split every 3 days and fresh media
containing cytokines was added. Cells that undergo early apoptosis were detected using
Annexin V while cells that undergo late apoptosis were detected using 7-AAD. Total
percent of apoptotic cells was represented as cells that were Annexin V+7-AAD+, while
the percent of living cells was represented as cells that were Annexin V-7-AAD-. The
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total number of living cells in culture under each condition and at each time point was
determined by trypan blue cell counts.
Our results showed that there was no significant difference in the percent of
apoptotic cells between cells that were treated with TSLP compared to untreated cells at
day 3 (Figure 4.4, top-left panel). Similarly, there was no significant difference in the
number of living cells in culture between cells that were treated with TSLP and those that
were untreated (Figure 4.4, bottom-left panel). However, at day 6 there was an increase in
the percent of apoptotic cells in the cultures that were treated with TSLP compared to
untreated controls (Figure 4.4, top-middle panel). In support of the observed increase in
the percent of apoptotic cells, we observed a decrease in the total number of living cells
present in the cultures that were treated with TSLP compared to the untreated control
(Figure 4.4, bottom-middle panel). Similarly, at day 9 we observed a pronounced increase
in the percent of apoptotic cells in the cultures that were treated with TSLP compared to
controls (Figure 4.4 top-right panel) and substantial decrease in the total number of living
cells in these cultures (Figure 4.4 bottom-right panel). Further, the percent apoptosis in
cells treated with TSLP at day 3 was very low (~20%) compared to day 6 (~50%) and
day 9 (~80%) (Figure 4.4). Overall, the data showed that TSLP induces apoptosis in
CRLF2 B-ALL cells in vitro which is increased at later time points, even though the
concentrations of TSLP that was administered at each time point remained the same.
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Figure 4.4 CRLF2 B-ALL cells were cultured in culture media with or without TSLP, IL7 or both for 3, 6 and 9 days. Cells were split every 3 days for the duration of experiment.
Cells were harvested and stained with Annexin V and 7-AAD and assessed by flow
cytometry. Graphs show the percent of apoptotic cells that are in the early stage (Annexin
V+-yellow) or late stage (7-AAD+- red) of apoptosis. Living cells are Annexin V-7-AADblue).

Since a component of the TSLP receptor (IL-7R ) is shared by the cytokine IL-7,
which is also produced by human BM stroma and is known to promote survival and
proliferation of human B-cells [28]; we also evaluated apoptosis in cells grown with or
without IL-7. Our results showed that at day 3, there was no difference in the percent of
apoptotic cells in cultures treated with IL-7 compared to untreated cells. Similarly, there
was no difference in the total number of living cells in the IL-7 cultures compared to the
untreated cells. At days 6 and 9, we also observed no difference in the percent of
apoptotic cells between the IL-7 cultures and controls, however, there was an increase in
the total number of living cells in the IL-7 cultures compared to the untreated controls on
days 6 and 9 (Figure 4.4). These data suggest that IL-7 increases cell survival by
protecting cells from apoptosis and may also be inducing cells to proliferate.
97

In summary, our in vitro culture studies suggest that TSLP reduces cell survival
by inducing apoptosis in cells while IL-7 increases cell survival by protecting cells from
apoptosis.. Additionally, the in vitro data provides further evidence to support the in vivo
data by demonstrating that TSLP induces apoptosis in CRLF2 B-ALL cells and
strengthens the molecular data which emphasized that TSLP induces cell death and cell
survival pathways.

TSLP Up-regulates Mcl-1 Expression as a Cell Survival Mechanism Prior to Inducing
Apoptosis in CRLF2 B-ALL Cells In vitro
The IPA data showed that cell death and survival are the most significant cellular
and molecular functions of the cell that are up-regulated by TSLP in primary CRLF2 BALL cells (Table 1). In addition, IPA also showed that while cell survival pathways such
as mTOR and cell metabolism are up-regulated, cell death (mitochondrial dysfunction)
and cellular stress pathways (EIF2 signaling) are also up-regulated by TSLP in these cells
(Figure 4.3). Moreover, although pathways that produce opposing cellular functions (cell
death versus survival) are activated by TSLP, the most significantly up-regulated
pathways are the cell death and cellular stress pathways. This idea is strikingly
demonstrated in the functional evidence provided by the in vitro data. The in vitro data
showed that at day 3, cells are maintained in culture, but they ultimately undergo
apoptosis at later time points. This data suggests that TSLP-induced signaling in CRLF2
B-ALL cells may involve regulation of the pro-survival versus pro-apoptotic switch.
Therefore we wanted to elucidate the mechanisms involved in the TSLP-induced survival
versus apoptosis.
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Apoptosis (programmed cell death) is a mechanism used by cells to regulate cell
numbers, to remove pathogens or to remove cellular debri and is often activated as a
result of DNA damage, loss of cell-survival factors or due to cellular stress. This process
may be intrinsic (initiated within the mitochondrion of the cell) or extrinsic (death
receptor mediated). Since the IPA data provided evidence that mitochondrial dysfunction
is up-regulated by TSLP in CRLF2 B-ALL cells, we focused our attention on
mitochondrial mechanisms that regulate the pro-apoptotic versus anti-apoptotic signals
within a cell. The intrinsic cell death pathway is regulated by the Bcl-2 family of proteins
[29]. These proteins function to regulate the permeability of the mitochondrial membrane
and to determine whether pro-apoptotic or anti-apoptotic signals will prevail in the cell
[23]. Under cellular stress conditions, Bcl-2 pro-apoptotic family members are activated
and direct the release of caspase activators in the mitochondria. Conversely, the Bcl-2
anti-apoptotic family members such as Bcl2, Bcl-xl and Mcl-1 are up-regulated to
prevent the cell from undergoing apoptosis and function to increase cell survival. In order
to understand the mechanisms involved in the survival of CRLF2 B-ALL cells at day 3,
we evaluated the expression of the anti-apoptotic Bcl2 family members in human CRLF2
B-ALL cell lines in vitro.
To accomplish this, first we cultured primary CRLF2 B-ALL cells that were
harvested from the BM of PDXs with or without TSLP for 3 days in vitro. At day 3, cells
were harvested from culture, hCD19+ B-ALL cells were isolated by magnetic separation
and cells were sent for whole genome microarray analysis. The DGA results showed that
there was no change in the gene expression profile of Bcl-2 family members (proapoptotic and pro-survival) except for Mcl-1. The data showed that Mcl-1 was up-
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regulated 1.6 fold in CRLF2 B-ALL cells that were treated with TSLP compared to
untreated cells in vitro.
Next, we cultured CRLF2 B-ALL cell lines with or without TSLP in vitro for 3
days and assessed the expression of Bcl-2 pro-survival proteins. At day 3, cells were
harvested from culture and the expression of Bcl-2 family pro-survival members Bcl-2,
Bcl-xl and Mcl-1 was measured using intracellular flow cytometry. Our data showed no
increases in Bcl-2 expression in cells stimulated with TSLP compared to untreated cells
(Figure 4.5 left panel). However there was a minimal increase in the expression of Bcl-xl
in TSLP treated cells (Figure 4.5 middle panel) and a substantial increase in the
expression of Mcl-1 in TSLP treated cells compared to controls (Figure 4.5, right panel).
Taken together the data shows that at day 3, TSLP has no effect on Bcl-2, but has an
effect on Bcl-xl and Mcl-1. The increases observed for Mcl-1 suggests that at day 3,
TSLP treated cells may be surviving primarily due to Mcl-1 expression. It is possible
that by days 6 and 9, the cellular stress induced by TSLP overcomes the Mcl-1-induced
pro-survival mechanisms and induces apoptosis in CRLF2 B-ALL cells in vitro.
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Figure 4.5: CRLF2 B-ALL cells were cultured in culture media with or without TSLP, IL7 or both for 3. Cells were split every 3 days for the duration of experiment. Cells were
harvested and stained with antibodies to Bcl-2, Bcl-xl, and Mcl-1 and assessed by
intracellular flow cytometry. Histograms of all conditions are overlaid (No cytokine – red;
TSLP- green; IL-7- blue; Both cytokines- orange).

We also evaluated the effects of IL-7 on the expression of Bcl-2 pro-survival
family members in CRLF2 B-ALL cells in vitro. The results showed that at day 3, IL-7
had no effect on Bcl-2 or Bcl-xl protein expression, however IL-7 increased Mcl-1
expression in CRLF2 B-ALL cells. Interestingly enough, the increase in Mcl-1
expression due to IL-7 stimulation was greater than that observed in cells that were
treated with TSLP. This data suggests that both cytokines have the ability to increase
Mcl-1 expression in this cellular system.
In summary our data provides evidence that TSLP maintains cell survival at 72
hrs by up-regulating Mcl-1, while TSLP induces apoptosis at later time points, possibly
due to the down-regulation of Mcl-1 over time in vitro. Future experiments that
investigate the expression of Mcl-1 and other Bcl-2 pro-survival family members at later
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time points (days 6 and 9) are required to confirm this hypothesis. In addition, the upregulation of Mcl-1 protein expression by TSLP and IL-7 suggests that 1) Mcl-1 plays a
crucial role in the cytokine-mediated survival of CRLF2 B-ALL cells and 2) provides
evidence that Mcl-1 is a potential molecular target that can be targeted by therapeutic
candidates in order to improve treatment outcomes for CRLF2 B-ALL.

Discussion
In normal B-cells, which express low levels of CRLF2, TSLP binds its receptor
and activates the JAK/STAT pathway to induce proliferation in these cells in vitro [7].
Using the hTSLP+/hTSLP- xenograft model, our studies provide additional data showing
that TSLP also induces survival in B-linage cells in vivo (chapter 3). In context of these
studies, using the hTSLP+/hTSLP- xenograft model, we evaluated the effects of TSLP on
CRLF2 B-ALL cells, which express higher levels of CRLF2. In this chapter, we
demonstrate that at the genetic level, TSLP induces genes involved in cell death and
survival pathways as well as genes involved in cell death and survival cellular and
molecular functions in CRLF2 B-ALL cells. At the cellular level, our results show that
TSLP induces apoptosis in CRLF2 B-ALL cells in vivo as well as in vitro. The findings
from this chapter which show that TSLP induces apoptosis in CRLF2 B-ALL cells
(CRLF2 high) is opposite to the findings from the previous chapter which show that
TSLP induces proliferation and survival in normal B-cells (CRLF2 low). These data
suggest that TSLP exerts different functional effects in normal B-cells, which express
low levels of CRLF2 and B-cell leukemia cells, which express high levels of CRLF2.
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A plausible explanation for the difference in functional effects that was observed
in normal B-cells stimulated with TSLP compared to CRLF2 B-ALL cells stimulated
with TSLP is the difference in activation of key mediators in TSLP-CRLF2 signaling
pathways. Studies of TSLP-induced pathways show that in normal B-cells, TSLP induces
weak activation of STAT5 (low level of pSTAT5), but is still able to induce proliferation
in B-cells [7]. Initial studies that were conducted to understand the signaling mechanisms
involved in CRLF2 B-ALL demonstrated that in the absence of TSLP, basal levels of
pSTAT5 were observed [9]. Further investigation of the pathways activated downstream
of CRLF2 in our studies show that TSLP increases the phosphorylation of STAT5 and
ribosomal protein S6 in CRLF2 B-ALL cells in vitro (chapter 1). Data from other studies
that evaluated the effects of TSLP on signaling pathways in CRLF2 B-ALL cells also
observed increases in the phosphorylation of STAT5, S6, AKT and ERK, thus supporting
our in vitro data [30]. Additionally, Tasian et al surmised that the observed increases in
phosphorylation of proteins that are key regulators of the JAK/STAT and mTOR
pathways suggests that there is increased activation of these pathways. Therefore they
hypothesized that aberrant signaling occurs in CRLF2 B-ALL cells. However, studies
conducted by Tasian et al did not address the long-term functions of TSLP (and this
aberrant signaling) on the maintenance and progression of CRLF2 B-ALL. Our studies
provide for the first time, evidence that shows that TSLP indeed induces aberrant
signaling in CRLF2 B-ALL cells (signaling that is different from normal B-cells) and that
this aberrant signaling results in the induction of apoptosis in CRLF2 B-ALL cells.
The mechanisms involved in the TSLP-induced apoptosis of cells are unclear.
Results from our IPA show that TSLP induces mitochondrial dysfunction and EIF2
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signaling in CRLF2 B-ALL cells, suggesting that the mechanisms may involve
mitochondrial-mediated cell death and the cellular stress pathway. A credible argument
that supports that TSLP may be inducing apoptosis via mitochondrion-mediated
mechanisms, is the fact that we see an involvement of the Bcl-2 family members. The
Bcl-2 family plays a pivotal role in regulating mitochondrial cell death and cell survival
[23, 29] and our evaluation of the Bcl-2 anti-apoptotic proteins showed that Mcl-1 may
be involved in maintaining the survival of CRLF2 B-ALL cells transiently prior to the
induction of apoptosis. Another argument is that TSLP may employ EIF2 signaling
pathways to induce cellular stress which overcomes cell survival mediated mechanisms
such as the up-regulation of Mcl-1, and contribute to apoptosis in CRLF2 B-ALL cells.
Studies have shown that environmental and/or endogenous stress signals can trigger the
phosphorylation of eIF2 - a major component of the EIF2 pathway [24]. Prolonged
activation of this pathway has been shown to induce apoptosis in cells [24]. Further,
studies have confirmed that phosphorylation of eIF2 is coupled to the mitochondrialmediated cell death machinery, which in turn down-regulates Mcl-1 expression, induces
activation of Bax and bak resulting in apoptosis. To further support this argument, other
studies have shown that Mcl-1 enhances the survival of hematopoietic cells and other cell
types that are placed under apoptosis-inducing conditions and this enhancement is often
short-term compared to that induced by Bcl2 [31]. Therefore studies that 1) evaluate the
expression of Mcl-1 at later time points when apoptosis is observed in CRLF2 B-ALL
cells and 2) evaluate the effects of TSLP on the expression of pro-apoptotic Bcl-2 family
members and caspases which are part of the cell death machinery for the intrinsic
pathway will provide evidence that validate the argument that TSLP induces apoptosis in
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CRLF2 B-ALL cells by activating the EIF2 cellular stress and the mitochondrial
pathways.
Overall,  TSLP’s  ability  to  induce  apoptosis  in  CRLF2 B-ALL cells provides a
rationale for conducting future studies that can evaluate its therapeutic potential in the
treatment of CRLF2 B-ALL. Further, the increased expression of Mcl-1 upon TSLP and
IL-7 stimulation, provide evidence that Mcl-1 is involved in cytokine-mediated
mechanisms and therefore provides a rationale for also evaluating the efficacy of mcl-1
inhibitors on CRLF2 B-ALL cells. If these studies are fruitful, then TSLP in combination
with Mcl-1 inhibitors may prove to be beneficial for the treatment of CRLF2 B-ALL.
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CHAPTER FIVE
IDENTIFICATION OF SMALL MOLECULE DRUGS THAT SHOW EFFICACY
AGAINST CRLF2 B-ALL AND OTHER HIGH-RISK B-ALL

Abstract
Patients diagnosed with high-risk B-ALL including CRLF2 B-ALL experience
high rates of relapse and poor patient survival outcomes. Current chemotherapy regimens
have been successful at achieving >95% remission rates, but they have been unsuccessful
at treating patients that relapse and subsequently experience a poor prognosis. The
success of Imatinib- a small molecule kinase inhibitor that targets the aberrant tyrosine
kinase that is encoded by the BCR-ABL oncogene- which was used in combination with
other chemotherapy agents to treat Ph+ hematological malignancies provided a paradigm
for the use of targeted therapy in high-risk cancers. Therefore, using a similar approach,
we identified two categories of small molecule drugs that are known to inhibit genetic
lesions and cellular processes involved in high-risk B-ALL cells and reduce cellular
survival. Here we show that the Mcl-1 inhibitor MIM1 showed efficacy by reducing the
survival of CRLF2 B-ALL cells in vitro. We also show that the NM drug series showed
efficacy by reducing the survival of chemo-resistant high-risk B-ALL cells in vitro and
increasing the survival of NSG mice in vivo. The drug candidates that were identified and
evaluated in these studies can be used for further preclinical testing on high-risk B-ALL
subsets in order to determine their therapeutic value. They offer the potential to be used
in combination with standard chemotherapy that is currently used to treat high-risk BALL.
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Abbreviations
ALL

Acute Lymphoblastic Leukemia

B-ALL

B-cell Acute Lymphoblastic Leukemia

MRD

Minimal Residual Disease

BCR-ABL

Breakpoint Cluster Region joined to ABL1 gene

CRLF2

Cytokine Receptor Like Factor 2

MIM1

Mcl-1 Inhibitor Molecule 1

Mcl-1

Myeloid Cell Leukemia 1

7-AAD

7-Amino-Actinomycin D

TSLP

Thymic Stromal Lymphopoietin

MTT

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NSG

NOD/SCID Gamma (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ)

DMSO

Dimethyl Sulfoxide

TKI

Tyrosine Kinase Inhibitor

ABT-737

Bcl-2, Bcl-xl and Bcl-w inhibitor

IL-7

Interleukin 7

IC50

Half maximal Inhibitory Concentration

110

Introduction
ALL is heterogeneous, thus treatment is administered based on phenotype,
genotype and risk factors [1]. Current therapies for high-risk ALL patients include
intense combination chemotherapy and/or allogenic bone marrow transplant [2].
Treatment for children with ALL is typically divided into two phases: 1) remissioninduction phase: this occurs at the time of diagnosis and the goal is to eradicate 99% of
initial leukemic cells and restore normal hematopoiesis; 2) post-induction therapy
phase: this occurs after complete remission and involves either intensification therapy
and/or continuation therapy to remove the residual disease [1, 3]. Remission-induction
chemotherapy consists of a combination of 3 drugs: vincristine, glucocorticoid
(prednisone or dexamethasone), and L-asparaginase or anthracycline in conjunction with
intrathecal therapy. In most cases, the result of such a combination is a complete
remission rate of greater than 95-98% in patients. Children with higher risk are often
treated with a combination of four or more drugs during induction therapy [1]. A
commonly used treatment regimen for high-risk childhood ALL include high-dose
methotrexate with mercaptopurine, high-dose asparaginase given for an extended period,
and re-induction treatment [4]. Tyrosine kinase inhibitors such as Imatinib are currently
used concurrently with chemotherapy to treat high-risk BCR-ABL+ ALL patients and
JAK recommended for clinical trials [5].
Despite the improvements, intense combination chemotherapy currently used to
treat high-risk B-ALL patients fails in ~25% of patients [6]. Patients experience relapse
and a poor prognosis with relapse being the leading cause of cancer-related death in
children [6, 7]. The current chemotherapy provides little scope for significant
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intensification because there are many short-term and long-term side effects in patients
due to toxicity and it has not been successful in reducing minimal residual disease (MRD)
and the incidence of relapse [5]. Most high-risk cases occur due to the presence of genetic
lesions in patient genotype that are unique to subsets of patients and are not targeted by
general chemotherapy. As a result, these genetic lesions contribute to MRD, relapse and
poor patient survival subsequent to remission. Therefore our goal was to identify
potential therapeutic candidates that can target molecular lesions that were identified in
chapter 4 and in previous studies and determine the efficacy of these drugs in decreasing
the survival of high-risk leukemia cells.
Here we evaluated the efficacy of the Mcl-1 inhibitor MIM1 and two new classes
of Novomedix small molecule drugs and demonstrated that these drugs have the ability to
reduce the survival CRLF2 B-ALL cells and high-risk B-ALL cells respectively.

Materials and Methods
In vitro Mcl-1 Inhibitor MTT Assay
CRLF2 B-ALL cell line was maintained in RPMI 1640 phenol red free medium
supplemented with penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 20% fetal
bovine serum (FBS). Cells were then cultured in the above media with varying
concentrations of Mcl-1 inhibitor MIM1 at 37oC and 5.0 % CO2 using a 96 well plate (in
triplicate). At 72 hrs, cells were removed and the MTT assay was performed using the
Vybrant MTT cell proliferation assay kit (Life Technologies). The plate containing the
cells was read using a microplate absorbance reader. Absorbance is read at 570nm.
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In vitro NM Drug Apoptosis Assay
Nalm6 cells were maintained in RPMI 1640 medium supplemented with
penicillin/streptomycin, L-glutamine, 50 uM 2-ME and 10% fetal bovine serum (FBS).
Cells were then cultured with the above media and NM drugs (735, 785 or 869) or
DMSO control for 48 hrs. Cells were harvested at 48 hrs and stained with Annexin V and
7-AAD to identify cells in early apoptotic (Annexin V+, 7-AAD–) or late apoptotic
(Annexin V+, 7-AAD+) stages using flow cytometry. The IC50 of the drug candidates
were obtained from the drug company and drugs were administered at their respective
IC50

In vivo NM Drug Efficacy Assay
NSG mice were transplanted with Nalm6 cells. Eight (8) days after
transplantation, drugs were administered to mice daily according to the following drug
conditions: 922, 1123, 911, vincristine, vehicle and untreated. Mice were evaluated daily
by observation and time of death was recorded in order to plot a survival curve.

Results
Mcl-1 Inhibitor MIM1 Reduces Cell Viability in CRLF2 B-ALL Cells In vitro
TSLP-induced up-regulation of the Mcl-1 gene and protein in CRLF2 B-ALL
cells described in chapter 4 and TSLP-induced up-regulation of Mcl-1 protein in IL-7R+
progenitors in normal B-cells described in chapter 3 supports the idea that Mcl-1 may
impact B-cells by contributing to cell survival. Further, the increases in Mcl-1 protein
expression observed in CRLF2 B-ALL cells upon TSLP stimulation and the increases in
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Mcl-1 expression as well as cell survival observed at later time points (days 6 and 9)
upon IL-7 stimulation, provide further evidence that Mcl-1 plays an important role in the
survival of B-ALL cells (chapter 4). Together, these data suggest that the regulation of in
CRLF2 B-ALL cells by TSLP and IL-7 induced signaling may be involved in adjusting
the apoptosis versus cell survival switch in these cells. Therefore, we hypothesized that
small molecule drugs, which target Mcl-l expression can reduce the survival of CRLF2
B-ALL cells in vitro. To test this hypothesis, we utilized a commercially available Mcl-1
inhibitor MIM1 to perform dose response experiments and evaluate its in vitro efficacy
on CRLF2 B-ALL cells using an enzyme-based cell viability, proliferation and function
test (a metabolic activity test). The MTT assay measures mitochondrial dehydrogenase
activity in living cells. In most cell types, the total mitochondrial activity is related to the
number of viable cells, therefore the MTT assay is often used as a drug screening assay
and as a measure of in vitro cytotoxicity of drugs on cell lines or primary cells [8].
CRLF2 B-ALL cells were cultured in culture media with varying concentrations of
MIM1 for 72 hrs. Cells were harvested and the MTT assay was performed. The results
from this dose response experiment showed that MIM1 reduced cell viability of CRLF2
B-ALL cells with an IC50 of 20 uM (Figure 5.1). At 30 uM, cell viability was reduced by
75%; between 50 uM and 100 uM, there were little to no viable cells present in culture
(Figure 5.1). These data suggest that MIM1 can induce reduction of CRLF2 B-ALL cell
viability  by  50%  at  concentrations  at  a  concentration  as  low  as  20  uM  and  that  MIM1’s  
cytotoxic  effects  are  increased  at  concentrations  ≥  30  uM.
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Figure 5.1: CRLF2 B-ALL cells (MUTZ5) were cultured with different concentrations of
MIM1 and harvested at 72 hours. Cells were washed, labeled with MTT. Samples were
read at an absorbance of 570nm.

NM Small Molecule Drugs Induce Apoptosis in Nalm6 B-ALL Cells In vitro
In order to identify other promising therapeutic candidates, our lab embarked on a
collaborative study with Novomedix Drug Company. Novomedix has developed two new
classes of small molecule drugs that can inhibit biological pathways, which often lead to
the development of diseases. Novomedix screened a library of 200 compounds that are
modulators of pathways involved in immune dysfunction and cancer. They identified: 1)
a tetrazole- 735 and its analog 869 and 2) a pyridine- 785 and its analog 790. 735 and 790
were subsequently submitted to the National Cancer Institute (NCI) for screening on a
panel of 60 human tumor cell lines. Both parent drugs were approved for testing,
indicating that their chemical structures were novel compared to existing anti-cancer
compounds which were tested by NCI. Novomedix subsequently found that the drugs
were safe based on in vitro toxicology studies conducted in primary lung fibroblast cells
and hepatocytes and in vivo toxicology studies conducted in CD-1 mice. Additional
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studies were performed to compare the efficacy of traditional chemotherapy drugs
currently used (e.g vincristine, dexamethasone) to NM drug series and the results
demonstrated that the NM drugs showed better efficacy on lymphoma cells and other
diseased cell types. Further mechanistic studies revealed that the NM drug series target
cell cycle proteins, cyclin D1 and D3.
Studies have shown that acute lymphoblastic leukemia patients that suffer relapse
often exhibit increased expression of cell cycle genes and proteins such as the cyclins
leading to protection from apoptosis, increased proliferation and increased cell survival
[9]. Therefore we hypothesized that NM drug series can target the cell cycle machinery
(genes) and reduce the survival of high-risk B-ALL cells. To test this hypothesis, we
performed drug efficacy studies on chemo-resistant B-ALL cells Nalm6, by assessing
cellular apoptosis using recommended IC50 concentrations. The IC50 of each drug was
determined by Novomedix using other cell types and they were as follows: 735 = 300nM;
785 = 430nM; 869 = 65nM. Nalm6 cells were cultured with NM compounds or DMSO
control. Cells were then harvested at 48 hrs and the Annexin V/7-AAD assay was
performed using flow cytometry. Percent apoptosis was determined by combining the
percent of cells in the early stages of apoptosis (Annexin V+) and the percent of cells in
the late stages of apoptosis (7-AAD+).
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Efficacy of Novomedix Drugs on B-ALL cells

Treatment
Figure 5.2: Nalm6 B-ALL cells were cultured with the Novomedix (NM) compounds 735,
785 and 869 or DMSO vehicle control. Cells were harvested at 48 hours and stained for
flow cytometry to detect Annexin V and 7-AAD. Percentages of cells that are living (green)
or apoptotic cells (Annexin V+7-AAD+ - red) are shown above.

Our data showed that all three drugs induced cellular apoptosis when compared to
cells treated with DMSO, however 735 and 869 were the most potent (Figure 5.2). 785
induced 25% apoptosis at 430 nM; 735 induced ~43% apoptosis at 300 nM and 869
induced 50% apoptosis at 65nM. The recommended IC50 for 785 was based on
assessments completed on other cell types by the company and as such was not the ideal
IC50 concentration for Nalm6 cells. Therefore further testing is required to determine the
optimum IC50 for 785 in this system. Our results suggest that a higher dose of 785 would
be required to show substantial efficacy against Nalm6 cells. Conversely, 869 shows the
most promise since it required a lower dose to achieve 50% cell death (IC50 nM). These
data suggest that Novomedix drugs 735 and 869 are promising drug candidates that can
be used to perform further testing to demonstrate their ability to reduce proliferation and
induce apoptosis in other subsets of high-risk B-ALL cells including CRLF2 B-ALL.

117

NM Small Molecule Drugs Increase the Survival of NSG Mice Transplanted with
Chemo-resistant B-ALL Cells In vivo
After we had determined the efficacy of NM drugs on high-risk B-ALL cells in
vitro, we investigated the efficacy of NM drugs in vivo by evaluating their effects on the
survival of NSG mice transplanted with high-risk B-ALL cells (Nalm6). Some of the
drug analogs for the NM735 and NM785 drug series were potent and successful at
inducing apoptosis of Nalm6 cells in vitro, however they proved to be toxic to animals
during in vivo safety testing. Therefore we selected analogs of NM735 and NM785 that
were successful during in vivo safety testing. Hence for in vivo drug efficacy studies, we
used NM1123, NM922 and NM911. Typically, NSG mice transplanted with Nalm6 cells
experience a poor survival outcome due to the aggressiveness of the disease, that is,
animals die between 18-21 days. Based on our in vitro results, we hypothesized that NM
drugs will increase the survival of NSG mice transplanted with Nalm6. To test this
hypothesis, NSG mice were transplanted with 1x107 Nalm6 cells per mouse
intravenously and 8 days after transplantation, drugs were administered daily via
intraperitoneal injections for 21 days or until the animals died. NM drugs were
administered at 25 mg/kg per mouse and vincristine was administered at 0.15 mg/kg per
mouse. Experimental groups were as follows: untreated, vehicle (DMSO only- negative
control), vincristine (positive control), NM1123, NM922 and NM911. For all groups,
n=5 mice except for the untreated group (n=2 mice), and NM1123 (n=6). Drug response
was assessed by 1) recording visual observations of animals daily and at time/day of
death and 2) recording the number of days treated animals lived compared to control
animals.
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NSG Mice Transplanted with Nalm-6 and Treated with Novomedix Drugs
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Figure 5.3: A survival curve showing percent survival of animals placed in 6 treatment
groups. NSG mice were transplanted with 1x107 Nalm6 cells and were treated with four
different candidate drugs: vincristine- positive control (red), NM1123 (green), NM922
(pink) and NM911 (blue). The negative controls groups were the no treatment group (grey)
and vehicle-DMSO group (black).

Our results showed that on day 18 (11 days post drug treatment) all untreated
animals died (Figure 5.3). By day19 (12 days post drug treatment), all vehicle (DMSO
treated) animals died. This time of survival (18-19 days) is typically observed for NSG
mice transplanted with Nalm6 cells only. All animals treated with NM911 died by day 18
(11 days post drug treatment). NM911 treated mice died earlier and on the day of
untreated mice. Visual observations of these mice revealed that they experienced anal
bleeding. These observations along with the time of death suggests that in addition to the
leukemia, NM911 treated animals may have died due to toxic effects of the drug. All NM
1123 treated animals died by day 22 (15 days post treatment) and the same was observed
for the vincristine controls. All NM 922 treated animals died by day 25 (18 days post
treatment). The survival curve summarizes the results and visually compares the data
obtained from each drug. In summary the data showed that vincristine and NM1123
increased the survival of Nalm6 NSG mice by 4 days (when compared to the untreated
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group), while NM922 increased the survival of these mice by 7 days. These in vivo
studies demonstrate that NM922 showed greater efficacy on Nalm6 cells compared to
vincristine and other NM drugs. NM922 is therefore a promising drug candidate that can
be used for further in vitro and in vivo preclinical testing to evaluate its effects on the
survival of several high-risk B-ALL subsets including CRLF2 B-ALL.

Discussion
With current therapies, ~25% of pediatric B-ALL patients still relapse and they
experience poor survival outcomes [5, 10]. Within this patient population, genomic
profiling studies have identified several high-risk B-ALL subtypes that are resistant to
chemotherapy, including those consisting of alterations in the BCR-ABL, IKZF1 or CRLF2
genes [5]. The translocation leading to the BCR-ABL+ B-ALL subtype was the first of
these genetic alterations to be identified and tyrosine kinase inhibitors (TKIs) that
specifically target the aberrant kinase activity produced by the BCR-ABL genetic defect
have been developed into drugs [11]. One such drug, Imatinib, when used in combination
with standard therapy, has increased the survival of children with BCR ABL+ B-ALL from
~35% to 80% [10, 12]. These studies provided a paradigm for identifying candidate drugs
that target specific genetic lesions or aberrant signaling pathways associated with high-risk
B-ALL, and using them in combination with standard therapy to improve survival
outcomes in children. We used a similar approach by identifying small molecule drugs that
are known to target molecular lesions/cellular pathways and evaluating the efficacy of
these drugs on high-risk B-ALL survival.
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Our results in chapter 4 showed that TSLP induced apoptosis in CRLF2 B-ALL
cells rendering it as a potential therapeutic to be considered for further preclinical drug
efficacy testing against CRLF2 B-ALL. In addition to inducing apoptosis, TSLP also upregulated Mcl-1 expression in CRLF2 B-ALL cells in vitro (chapter 4). An increase in Mcl1 expression was also observed when CRLF2 B-ALL cells were stimulated with IL-7
(chapter 4). Mcl-1 has been shown to regulate the survival of many cells and is often upregulated in cancer cells [13]. Therefore we assessed the efficacy of the Mcl-1 inhibitor
MIM1 on CRLF2 high-risk B-ALL and our results showed that MIM1 showed efficacy by
significantly reducing the survival of these cells. The mechanisms by which MIM1 reduces
the survival of CRLF2 B-ALL cells remain to be elucidated. Future studies that assess the
mechanisms  involved  in  MIM1’s  ability  to  inhibit  the  expression  of  Mcl-1 in CRLF2 BALL cells in vitro and the ability of MIM1 to reduce bone marrow disease in vivo are
required. Additionally, it will be important to assess the effects of other Mcl-1 inhibitors
such as Maritoclax and other Bcl-2 family inhibitors such as ABT-737 in context of MIM1
in order to fully validate the therapeutic value of Mcl-1 inhibitors on the CRLF2 B-ALL
high-risk subset of leukemia.
In most high-risk B-ALL, cells increase in numbers by undergoing proliferation
and cyclins have been shown to contribute to this process [14-16]. Thus we assessed the
efficacy of a new class of small molecule drugs (NM lead series) on chemo-resistant
high-risk B-ALL. Our results showed that NM735 and NM869 showed efficacy by
reducing the survival of Nalm6 cells in vitro, while NM 922 and NM1123 (analogs of
735 and 869) showed in vivo efficacy by increasing the survival of Nalm6 NSG mice
compared to untreated controls. NM drugs (NM1123 and NM922) showed efficacy that
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was similar or better than vincristine- a chemotherapy drug that is currently used as part
of the treatment regimen for patients with high-risk leukemia. Vincristine is considered to
be among the most potent drugs, however, it is toxic to patients at high concentrations
[17]. The vincristine effects that we observed in mice was based on daily administration
of the drug, while in current practice, it is administered to patients once per week. Thus
the effects we see are at high doses, which would be toxic for patients and would
undermine the true effects of NM922. Future experiments conducted to evaluate NM
drugs in context of less frequent dosing (weekly as opposed to daily) of vincristine are
required in order to optimize the in vivo effects observed for NM922 in high-risk B-ALL
cells. Additionally, NM drug series should be tested on other subsets of high-risk B-ALL
including CRLF2 B-ALL cells to fully evaluate its therapeutic value.
Improved remission rates in recent years are primarily due to the administration of
higher doses of standard chemotherapy [7]. However, these higher doses have resulted in
increased toxicity and side effects for patients and to compound this, they have been
ineffective in reducing the relapse-rate of CRLF2 B-ALL and other high-risk B-ALL [7,
18, 19]. Targeted therapy is therefore advantageous in that it can decrease toxicity by
targeting distinct cell lineages, cell cycle proteins or dysfunctional tumor suppressors
which all contribute to relapse but are often not targeted using current treatment
regimens. Our studies provide evidence of the efficacy of two categories of drugs, which
target molecular lesions and oncogenic cellular processes that can be used for further
preclinical testing on CRLF2 B-ALL and other high-risk B-ALL. They offer the potential
to be used in combination with reduced doses of standard therapy while increasing
overall efficacy of treatment in high-risk B-ALL.
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CHAPTER SIX
DISCUSSION

Summary of Chapter Findings and Relevance to the Leukemia Field
The objective of my dissertation studies was to elucidate the TSLP-CRLF2mediated cellular and molecular mechanisms that contribute to high-risk CRLF2 B-ALL
and to evaluate promising drug candidates to target CRLF2 B-ALL and other high-risk
B-ALL. Our working hypothesis was that TSLP contributes to CRLF2 B-ALL by
increasing proliferation and/or survival of leukemia cells via regulation of genes
downstream of CRLF2 pathway activation. To accomplish our objective, we developed
three aims. The first aim was to optimize the novel hTSLP+/hTSLP- xenograft model for
use in defining the role of TSLP in CRLF2 B-ALL; the second aim was to identify TSLPinduced cellular and molecular mechanisms that contribute to CRLF2 B-ALL; and the
third aim was to assess candidate  drugs’  efficacy  against  high-risk B-ALL.
The molecular mechanisms that contribute to the development and maintenance
of high-risk B-ALL that are linked to the recently discovered CRLF2 genetic defect
remain unclear and despite the success of current therapeutic strategies with some highrisk B-ALL, CRLF2 B-ALL patients still experience at a 65% relapse rate [1]. Research
groups that currently study CRLF2 B-ALL are focused primarily on genomic profiling
studies, the identification of molecular lesions within CRLF2 pathways such as JAK2
mutations and aberrant signaling of the JAK-STAT and mTOR pathways [1-7]. This
current direction of the field is based upon studies conducted using a BaF3 model systeman IL-3-dependent murine cell line transduced with mutant JAK and/or mutant CRLF2
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[5, 6]. In these studies, researchers demonstrated that cells that overexpress CRLF2 (due
to the presence of CRLF2 genetic defects) and consist of mutations in JAK2 showed
constitutive activation of JAK/STAT signaling and cytokine independent growth, which
was enough to transform cells [5, 6, 8]. These results were not observed in BaF3 cells
that harbored CRLF2 overexpression alone or in cells with JAK2 mutations alone [5].
Further co-immunoprecipitation studies demonstrated that human CRLF2 and
phosphorylated mutant JAK2 interact physically [5]. Therefore the current hypothesis in
the field is that CRLF2 and JAK2 cooperate to lead to leukemogenesis [9, 10] and the
contributions of TSLP-the endogenous ligand for CRLF2- to the disease mechanisms of
CRLF2 B-ALL remain to be elucidated.
Our approach to understanding CRLF2 B-ALL disease mechanisms was to
determine the effects of TSLP on the disease. To do this, as proposed in aim 1, first we
developed and optimized a novel hTSLP+/hTSLP- model system described in chapter 2.
The rationale for developing this model was based on the fact that mouse TSLP does not
activate human CRLF2 BALL cells in vitro. To confirm that the human TSLP produced
in our model acts on human cells; using the human TSLP in vivo model system, we
demonstrated that human TSLP signals produced in the model activates human CRLF2
on normal B-cells and increases the number of CD19+ B-cells in the bone marrow
(chapter 2). It is established in the field that TSLP induces proliferation of normal murine
B-cells and it was more recently shown that TSLP induces proliferation of human fetal Bcells in vitro [11, 12]. Therefore, the ability of the human TSLP produced in our model to
expand normal B-cells confirmed the previously published findings and provided the first
in vivo data, all of which served as a validation of the model. Next we confirmed that
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TSLP produced in the model also activates CRLF2 B-ALL cells in vivo. Our results
showed that the TSLP produced in the model up-regulated one of the main TSLP-CRLF2
pathways, the mTOR pathway, in CRLF2 B-ALL cells in vivo [13]. Other groups have
shown that TSLP activates the mTOR pathway in pre-B ALL cells and in CRLF2 B-ALL
cells in vitro [7, 14, 15]. Thus, the ability of the human TSLP produced in our model to
induce the mTOR pathway in CRLF2 B-ALL cells in vivo provided additional validation
for the hTSLP model system. Moreover, this is the first study to produce a
hTSLP+/hTSLP- human-mouse xenograft system and it is the first demonstration of the
use of this system to induce B-lymphopoiesis in normal B-cells (chapters 2, 3) and
activate TSLP-regulated pathways in CRLF2 B-ALL cells in vivo (chapter 2).
In order to further delineate the mechanisms of TSLP-induced signaling in
CRLF2 B-ALL cells as proposed in aim 2, our approach was to first understand the
TSLP-induced mechanisms in normal B-cells and then use this as a framework for
evaluating and understanding the contributions of TSLP to the disease mechanisms
involved in CRLF2 B-ALL cells. Using the hTSLP+/hTSLP- model system, we
demonstrated that TSLP up-regulates Mcl-1 and induces proliferation of CD19–
CD34+IL7R + progenitors, resulting in a 3-4-fold expansion of the CD34+ pro-B cells;
and that this expansion is maintained during the subsequent stages of B-cell development
(chapter 3). Additionally, the data showed that the observed increases in B-cell numbers
were due not only to proliferation, but also due to protection from apoptosis (chapter 3).
Though the roles of TSLP and IL-7 have been well studied in murine B-cell
development, the roles of both cytokines in human B-cell development remained
controversial. Our studies are significant in that the hTSLP+/hTSLP- model system
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provides both cytokines (human TSLP which is species-specific and murine IL-7 which
is cross-reactive) allowing the opportunity to study the effects of TSLP in context of IL-7
for the first time in vivo. Our studies were also significant in that they introduced for the
first time a survival role for TSLP in human B-cells, which is distinctly different from the
roles of IL-7  (chapter  3).  Moreover,  TSLP’s  effect  on  normal  B-cells provides evidence
that supports our hypothesis stated in the first paragraph of this discussion.
After confirming that the human TSLP in our model can activate normal human
B-cells, which express low levels of CRLF2; we used the hTSLP+/hTSLP- in vivo model
system to evaluate the effects of TSLP on CRLF2 B-ALL cells, which express high
levels of CRLF2. Our results showed that at low levels of TSLP, there was no difference
in the percent of CRLF2 B-ALL cells that were engrafted in the bone marrow of PDXs
(chapter 4). However, assessment of the percent of viable CD19+ cells showed that of the
cells that were engrafted, there was an increase in the percent of apoptotic cells in the +T
mice compared to the –T mice. When higher levels of TSLP were added, there was little
to no leukemia cells engrafted in the BM (chapter 4). Microarray results comparing gene
expression patterns from CRLF2 B-ALL cells expanded in +T mice compared to –T
mice, showed that TSLP up-regulates genes that are involved in cell death and survival
functions of the cell (chapter 4). Additional genetic data showed that TSLP also upregulates genes that are involved in cell death and survival signaling pathways; the cell
death pathways being more significant (chapter 4). The genetic data provided evidence to
support the in vivo data showing that TSLP regulates both cell death and survival
mechanisms, but primarily induces apoptosis in CRLF2 B-ALL cells in vivo. Therefore
we performed in vitro experiments  to  further  confirm  TSLP’s  effects  on  these  cells. This
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was accomplished by assessing the survival of cells stimulated with TSLP in vitro. Our
results showed that TSLP increased Mcl-1 expression and maintained cell survival at
early time points, but later induced apoptosis in CRLF2 B-ALL cells (chapter 4). These
studies are the first to evaluate the long-term functional effects of TSLP on CRLF2 BALL cells in vitro and more importantly in vivo thereby introducing a novel role for
TSLP as a possible therapeutic candidate. Interestingly, the data showing that TSLP
induces apoptosis in CRLF2 B-ALL does not support our hypothesis stated in paragraph
1 of this discussion. Therefore future studies that further elucidate the mechanisms by
which TSLP exerts its effects are required to fully understand its role in the disease and
its therapeutic value. We also identified Mcl-1 as a potential molecular target that can be
considered for inhibitor studies against CRLF2 B-ALL.
Patients diagnosed with CRLF2 B-ALL still experience higher rates of relapse
and currently no targeted treatment exists [1]. Studies have recommended the use of JAK
inhibitors in clinical trials for the treatment of Ph-like ALL, including CRLF2 B-ALL,
however preclinical and clinical testing are still underway and not all CRLF2 leukemias
harbor JAK mutations [16, 17]. Therefore there is a need for the testing of drug
candidates that the offer potential to induce cytotoxic effects on CRLF2 B-ALL cells. We
addressed this need in aim 3, which was accomplished by conducting drug efficacy
studies against CRLF2 B-ALL and other high-risk B-ALL cells (chapter 5). Results
showing that TSLP induces apoptosis in CRLF2 B-ALL cells require further testing, but
provide evidence that TSLP can be considered as a lucrative potential therapy for CRLF2
B-ALL (chapter 4). Based on the results which showed that TSLP also increased the
expression of Mcl-1, a Bcl-2 family member which functions to increase cell survival, we
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evaluated the efficacy of the Mcl-1 inhibitor MIM1 on CRLF2 B-ALL cells in vitro
(chapter 5). Our results showed that MIM1 reduced the viability of CRLF2 B-ALL cells
and showed cytotoxic effects as MIM1’s concentration was increased; proposing MIM1
as another drug candidate that can be used for further efficacy studies against CRLF2 BALL (chapter 5). In vitro and in vivo drug efficacy studies were also performed on
another subset of high-risk B-ALL that is chemo-resistant using a new class of drugs
(NM drug series), which inhibit cyclin-D-mediated proliferation in cells. The results
showed that NM735 and NM869 showed efficacy against chemo-resistant B-ALL cells in
vitro and NM922 showed efficacy against these same cells in vivo (chapter 5). The NM
series are potential candidates that can be used for further efficacy studies against chemoresistant B-ALL and other high-risk B-ALL such as CRLF2 B-ALL. Taken together, we
have identified 3 potential candidates that can be used for further preclinical efficacy
studies against CRLF2 B-ALL.

Conclusions and Future Implications
Overall, our studies were significant because 1) we were able to develop and
optimize a novel xenograft model that provides human TSLP in vivo; 2) we used the
human TSLP model to further investigate the TSLP-induced mechanisms involved in
CRLF2 B-ALL (against a backdrop of normal B-lymphopoeisis); 3) we identified drug
candidates that can be furthered evaluated as potential therapies for the treatment of
CRLF2 B-ALL. Our studies provide new data that will contribute to a new understanding
in the field of CRLF2 B-ALL disease mechanisms in context of TSLP. There are several
points to consider as we assimilate this new data. First, it is difficult to study the role of
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TSLP in CRLF2 B-ALL in vivo because current xenograft models that are used to study
pediatric acute lymphoblastic leukemia lack human TSLP. PDXs are successful because
most mouse cytokines are cross-reactive, having the ability to act on human leukemia
cells and provide the growth signals that are necessary for these cells to expand in vivo
[18]. However, TSLP is species specific [18]. The hTSLP+/hTSLP- model described in
these studies provides the human TSLP that is required to design experiments that
address the TSLP-mediated disease mechanisms of CRLF2 B-ALL and conduct
preclinical testing of potential therapeutic candidates. Second, the TSLP-mediated
signaling and cellular functions in CRLF2 B-ALL  are  different  from  TSLP’s  functions in
normal cells. In normal B-cells, TSLP activates the JAK/STAT pathway and induces
proliferation [12]. In CRLF2 B-ALL cells, basal levels of pJAK2, pSTAT5 and pS6 are
present in the absence of TSLP, which is hypothesized as contributing to the constitutive
activation of the JAK/STAT pathway (aberrant signaling) and leading to enhanced
leukemia cell growth [6, 19]. Further, CRLF2 B-ALL cells stimulated with TSLP show
increases in pSTAT5, and pS6 compared to untreated cells that express basal levels of
pSTAT5, suggesting further increases in the activation of JAK/STAT and
PI3K/AKT/mTOR pathway [7]. However, our functional studies (in vitro and in vivo)
described in the previous chapters, show that though there is increased pSTAT5 and pS6
in the presence of TSLP with which we would expect to see increased proliferation
compared to normal B-cells or untreated CRLF2 B-ALL cells, instead we observed the
induction of apoptosis (chapters 2 and 4). Our studies show that stimulating CRLF2 BALL cells with TSLP reduces the survival of these cells by inducing apoptosis,
suggesting that the TSLP-mediated signaling is not only different from what occurs in
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normal B-cells, but is also different from what occurs in the leukemia cells in the absence
of TSLP (Figure 6). This finding is paradigm shifting and has major future implications
for understanding the disease mechanism of CRLF2 B-ALL and the designing of
treatment strategies for the treatment of the disease.
Therefore the major questions that remain to be addressed are: 1) what
mechanisms are involved in the TSLP-induced apoptosis of CRLF2 B-ALL?; 2) to what
end does TSLP induce apoptosis in CRLF2 B-ALL cells?; 3) is TSLP inducing apoptosis
to eradicate cancer cells thereby rendering it as a potential therapeutic candidate for the
treatment of CRLF2 B-ALL?; 4) what is the therapeutic value of TSLP in relation to the
treatment of CRLF2 B-ALL? 5) or is it a mechanism used by TSLP to regulate the
cellular apoptosis versus cell survival switch in order to produce resilient clones of cells
that can resist chemotherapy treatment and later contribute to MRD and relapse? Future
studies that are designed to answer these questions will provide a basis for fully
elucidating the involvement of TSLP in the initiation, maintenance and/or progression of
CRLF2 B-ALL.
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Figure 6: TSLP-induced Mechanisms in CRLF2 B-ALL. This cartoon serves as a visual
illustration to show the differences in CRLF2 B-ALL mechanisms in the absence and
presence of TSLP.
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APPENDIX A (CHAPTER 2)
SUPPLEMENTAL MATERIALS
Supplemental Methods
Cell Culture Media
MUTZ5 and MHH-CALL4 were maintained in RPMI 1640 medium (Irvine
Scientific, Santa Ana, CA) supplemented with penicillin/streptomycin, L-glutamine, 50
uM 2-ME and 20% FBS (Omega Scientific, Tarzana, CA). This media was also used for
in vitro cultures with and without TSLP (both for phospho-flow assays and for gene
expression profiling in response to TSLP). HS27 stroma were maintained in RPMI 1640
medium (Irvine Scientific) supplemented with penicillin/streptomycin, L-glutamine, 50
uM 2-ME and 10% FBS (Omega Scientific).
Flow Cytometry
Cells were prepared for surface antigen detection and assessed by flow cytometry
using protocols described in companion paper. Dead cells were identified using fixable
viability dye as described in companion paper. Specific antibody clones and conjugates
are shown below.
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Table 2. List of Antibodies, Clones and Manufacturer Information 1 (chapter 2).
Antibody

Clone

Manufacturer

Ig  κ  light  chain  FITC

G20-193 BD Pharmingen (San Jose, CA)

Ig  λ  light  chain  FITC

JDC-12

Anti-phospho STAT5 (pY694) PE

47/Stat5
(pY694)

Anti-Phospho AKT (pS473) Alexa Fluor 488

M89-61

Anti-Phospho S6 (pS235/S236) Alexa Fluor
488

N7-548

CD34 PerCP

581

CD19 APC

HIB19

TSLPR APC

1B4

CD19 APC

HIB19

CD19 PE.Cy7

SJ25C1

CD45 PE.Cy7

HI30

Anti-Mouse CD45 FITC

30F11

CD19 APC

LT19

CD127 PE (IL-7Ra)

MB1518C9

BD Biosciences (San Jose, CA

BioLegend (San Diego, CA)

eBioscience (San Diego, CA)

Miltenyi Biotec (Auburn, CA)

Phospho-flow Cytometry Staining
Human CRLF2 B-ALL cell lines were harvested from continuous culture and
primary CRLF2 B-ALL cells were obtained as BM from patient-derived xenografts. Cells
were rested in culture without cytokines for 2 hrs, and then cultured with mTSLP, hTSLP
or no cytokine for 30 mins (S6 and AKT) or 1 hour (STAT5). Cells were then harvested
and stained with antibody to phosphorylated STAT5 (pSTAT5), AKT (pAKT) or S6
(pS6) as previously described for STAT5 (1). Primary CRLF2 B-ALL patient-derived
samples were also stained with CD19 APC prior to fixation and permeabilization for
detection of phospho proteins and CD19+ cells were gated for phospho-flow cytometry
plots.
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ELISA Assays of TSLP
Concentrations of hTSLP in the supernatant of transduced HS27 stromal culture
and in sera collected from NSG mice injected with transduced stroma were measured
using the Human TSLP ELISA MAX Kit (BioLegend, San Diego, CA). Stromal cell
supernatants were harvested from confluent flasks when stromal cells were passaged
(typically two times per week) and sera was obtained from mice at weekly time points at
the time of weekly stromal cell injection. Data was collected using the uQuant microplate
spectrophotometer (BioTek Instruments Inc., Winooski, VT) and analyzed using the KC
Junior, version 1.6 (BioTek Instruments, Inc., Winooski, VT)
Lentiviral Vector and TSLP-expressing Human Stromal Cells
TSLP vector was generated using standard molecular cloning techniques with
complementary DNA encoding human TSLP (purchased from Thermo Scientific Open
Biosystems). In this vector, the EF-1α  promoter  was  used  to  drive  TSLP  expression.  A  
control vector with GFP was also generated. The lentiviral vector packaging and titering
were performed as previously described (2). In brief, VSV-G–pseudotyped lentiviral
vectors were prepared by calcium phosphate–mediated 3-plasmid transfection of 293T
cells. Briefly, 27 µg transfer vector construct, 17.5 µg second-generation gag-pol
packaging construct pCMV.R8.74, and 9.5 µg VSV-G expression construct pMD2.G
were used for transfection of 12x106 293T cells overnight in 25 ml DMEM with 10%
fetal bovine serum. The cells were treated with 10 mM sodium butyrate during the first of
three 12-hour vector supernatant collections. The supernatant was filtered through 0.22µm-pore-size filters and concentrated 100-fold by ultracentrifugation before freezing and
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storing at –80° C. All vector stocks were titered by transducing HT1080 cells with
analysis for GFP expression by flow cytometry or real-time PCR.
Processing of Samples from Xenograft Mice
Flow cytometry analysis of peripheral blood (PB) was used to establish
chimerism with human cells prior to euthanasia. PB was collected using tail-tip excision
(tail nick) and placed into a microtainer serum separator tube (BD Gold, 200/cs). Samples
were centrifuged at 1500 rpm for 15 mins. Serum was removed for ELISA analysis.
Blood cells were subjected to red blood cell lysis (3) and remaining white blood cells
were stained for human surface markers. NSG mice were euthanized 5-7 weeks after CB
CD34+ transplantation or 9 weeks after CRLF2 B-ALL transplantation. On the day of
euthanasia fresh Bone Marrow (BM), spleen and PB were harvested. Single cell
suspensions were obtained from the BM by using 26g syringe and PBS to flush the
femora and humeri and by filtering cells with a 70 micron cell strainer (BD Biosciences,
San Jose, CA). Cells obtained from all tissues were stained immediately for flow
cytometry analysis or were frozen for future use.
Microarray Analysis of Gene Expression in CRLF2 B-ALL Cells
Mice engineered to be +T and –T by stromal cell injection were transplanted with
primary CRLF2 B-ALL cells from a Hispanic pediatric patient. Following transplant,
mice received weekly intraperitoneal injection of 5X106 +T or –T stroma from
Transduction 1 (see Results section). Nine weeks post transplant, BM was harvested and
frozen for later use. For microarray to evaluate in vivo TSLP-induced changes in gene
expression, xenograft BM was thawed and human B-ALL cells were isolated by
magnetic separation using the Human CD19 microbead kit (Miltenyi Biotec, Inc., San
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Diego,  CA)  according  to  manufacturer’s  protocol  and  rapidly  frozen  on  dry  ice  (Samples  
E1-E3 and F1-F3 described below). For microarray to evaluate in vitro TSLP-induced
changes in gene expression (Fig. 4), xenograft BM was thawed and cultured in vitro for 3
days with TSLP at 15ng/ml or without TSLP and with neutralizing anti-TSLP antibody
(R&D Systems, Minneapolis, MN) or control antibody (Jackson ImmunoResearch).
Following culture, cells were harvested and thawed and human B-ALL cells were
isolated by magnetic separation using the Human CD19 Microbead Kit according to
manufacturer’s  protocol  and  rapidly  frozen  on  dry  ice  (samples  A1-A3, B1-B3, C1-C3
and D1-D3 as described below). Frozen cells were shipped to Miltenyi Biotec (Miltenyi
Genomic Services) for RNA isolation, sample preparation, whole genome microarray,
and discriminatory gene analysis (DGA) as follows:
Total RNA Isolation. Human total RNA was isolated using the NucleoSpin®
RNA kit (Macherey-Nagel, Bethlehem, PA). RNA quality and integrity were determined
using the Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). RNA was quantified by measuring A260nm on the ND1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).
RNA Amplification and Labelling. Sample labelling was performed as detailed in
the  “One-Color Microarray-Based Gene Expression Analysis protocol (version 6.6, part
number G4140-90040). Briefly, 50 ng RNA for the samples from groups A, B, E and F,
10 ng RNA for the samples of group C and D, and the complete available amount of
RNA for the samples C3 and D1 was used for the amplification and labelling step using
the Agilent Low Input Quick Amp Labelling Kit (Agilent Technologies). Yields of
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cRNA and the dye-incorporation rate were measured with the ND-1000
Spectrophotometer (NanoDrop Technologies).

Table 3. Microarray Sample Key.
Sample

Source of Cells

In vitro Culture, Condition

A1, A2, A3

CRLF2 B-ALL cells from +T mice

Yes, +TSLP

B1, B2, B3

CRLF2 B-ALL cells from +T mice

Yes, –TSLP

C1, C2, C3

CRLF2 B-ALL cells from –T mice

Yes, +TSLP

D1, D2, D3

CRLF2 B-ALL cells from –T mice

Yes, –TSLP

E1, E2, E3

CRLF2 B-ALL cells from +T mice

No, ----------

F1, F2, F3

CRLF2 B-ALL cells from –T mice

No, ----------

Hybridization of Agilent Whole Human Genome Oligo Microarrays. The
hybridization  procedure  was  performed  according  to  the  “One-Color Microarray-Based
Gene Expression Analysis protocol (version 6.6, part number G4140-90040) using the
Agilent Gene Expression Hybridization Kit (Agilent Technologies). Briefly, 0.6 µg Cy3labeled fragmented cRNA in hybridization buffer was hybridized overnight (17 hours, 65
°C) to Agilent Whole Human Genome Oligo Microarrays 8x60K v2 (AMADID 039494)
using  Agilent’s  recommended  hybridization  chamber  and  oven.  Following  hybridization,  
the microarrays were washed once with the Agilent Gene Expression Wash Buffer 1 for 1
min at room temperature followed by a second wash with preheated Agilent Gene
Expression Wash Buffer 2 (37 °C) for 1 min.
Scanning and Data Analysis: Fluorescence signals of the hybridized Agilent
Microarrays  were  detected  using  Agilent’s  Microarray  Scanner  System  G2505C  (Agilent  
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Technologies). The Agilent Feature Extraction Software (FES) 10.7.3.1 was used to read
out and process the microarray image files.
Discriminatory Gene Expression Analysis. After probe summarization, quantile
normalization and log2 transformation, differentially expressed genes were identified by
a combination of effect size and statistical significance. For the analysis of the individual
comparisons, only reporters with an at least two-fold median up- or downregulation in +T
samples compared to –T samples and an adjusted p-value  (Student’s  t-test, two-tailed,
equal variance, Benjamini-Hochberg  correction  for  multiple  testing)  p≤0.05  were  
considered relevant. In an additional filtering step, only Agilent reporters with signal
intensity values significantly above local background (p<0.01 as calculated by the
Rosetta Resolver® gene expression data analysis system) in at least two samples of the
group with higher median expression were selected (4). All microarray data reported in
this  publication  were  deposited  in  the  NCBI’s  Gene  Expression  Omnibus  at  National  
Center for Biotechnology Information and are accessible via the GEO series accession
number GSE65274.
Real Time Quantitative RT-PCR
Expression of select genes observed in microarray results was validated using
quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR) using primers
shown  below.    Total  RNA  (2.0μg)  was  reverse  transcribed  using  poly  d(T)20  primers  and  
SuperScript II reverse transcriptase (Life Technologies, Grand Island, NY). The resulting
cDNAs were used for qRT-PCR analysis of their mRNA levels on a StepOne Plus 7500
Real-time PCR system (Applied Bioscience Inc., Foster City, CA) using specific primers
for each gene (see supplemental table 2 for primer sequences) following the

142

manufacturer's instructions. The fluorescence threshold value was calculated and
normalized to the values of 18s rRNA. The fold change in mRNA expression of genes
between the TSLP-treated W31 cell group versus untreated group was achieved by the
ratio of fluorescence threshold value in the treated groups versus that of the untreated
group. The fold change for each gene was paired with that of microarray analysis. Linear
regression analysis of the fold change versus that of microarray was performed with
Origin 6.0. The graph shows the best-fit line, the formula for the best-fit line (Y = a +
bX), its correlation coefficient (r), and the probability (P) that the r value is a false
positive.

Table 4. Primer List for Genes Validated by qRT-PCR
Gene

Forward Primer

Reverse Primer

BIVM

5’-GGCCAGAGGCAATGCAAAG

5’-TGAGGTCTAATACTTTCCGCTGT

PTH2

5’-CTGGTTCTCCACAGGTGATG

5’-CATGTACGAGTTCAGCCACT

FOSL2

5’-AACACCCTGTTTCCTCTCCG

5’-ATCTACCCGGAATTTCTGCGG

RAMP1

5’-GCAGGACCATCAGGAGCTACA

5’-GCCTACACAATGCCCTCAGTG

SLC4A8

5’-TGGGTCCAGTAGGGAAAGGT

5’-ACCGTCACCTGGTCTAGGAA

NR4A2

5’-GTAACTCGGCTGAAGCCATGC

5’-GTCGTAGCCTGTGCTGTAGTT

KCNH8

5’- GCAAGATCAATTTGCATCCACTAT

5’- AAGGCAGGGCAGCGATTA

THSD7A

5’- CCATCTCGAGTCTTTGTTCACATT

5’- CATTTGGGAATTGTGCTTCTCA

RAB26

5’-CCAGGCCCTTCTGACTTTGT

5’-CTGCTTGTTGGGACTGTTGC

RGS1

5’-CTCCCTGGGTGAACAGCTTG

5’-GCTTCTTCAACTCTGCGCCT

NELL1

5’-GATATGAAGCCACCCGTGTT

5’-CTGAAGGTCAGGGTCCATCC

MDF1

5’-GAAGTTGCAGACACACCCATCTC

5’-GTCCAGGACGATGTTGCACAG

KREMEN2

5’-TGAGGACCCAGAGGCCC

5’-CAGACAGCTCCCCCAATCG

CPNE8

5’-CGCCTCCTCCCAATATGGAC

5’-ATTTCTGCAGGACACGGACA

Gene Set Enrichment Analysis
Microarray data was evaluated at the level of gene sets to define and quantitate
trends in gene expression similar to published data. Ranked gene lists were created and
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submitted to the online public repository provided by the BROAD Institute for Gene Set
Enrichment Analysis (GSEA) (5, 6) to evaluate Oncogenic Signatures that are enriched in
CRLF2 B-ALL cells expanded in +T as compared to –T mice
(www.broadinstitute.org/gsea).

Ingenuity Pathway Analysis
The complete list of differentially expressed genes obtained from microarray
datasets were uploaded and analyzed using the Ingenuity Pathway Analysis tool (IPA;
Ingenuity Systems, Redwood City, CA) to identify significant biological pathways that
are up-regulated in CRLF2 B-ALL cells expanded in +T compared to –T mice. The
pathways  were  identified  using  the  “Canonical  Pathway”  feature  of  IPA.  The  activity  of  a  
pathway was deemed significant if its p-value is less than or equal to 0.05 and is
calculated using the right-tailed Fisher Exact Test.
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Supplemental Figures

Figure 1: Expression of CRLF2 and IL-7R on normal human B cell precursors and
CRLF2 B-ALL harvested from xenograft mice. (A) Bone marrow was harvested from
xenograft mice transplanted with human CD34+ cord blood cells or and stained for flow
cytometry. Plotted is CRLF2 and IL-7Ra expression on B cell precursors (hCD19+ and Ig
kappa & lambda–) B) Bone marrow was harvested from a patient-derived xenograft
generated using the primary CRLF2 B-ALL sample shown in Fig. 1B, right panel. Plotted
is the CRLF2 and IL-7Ra on human CRLF2 B-ALL (hCD19+) cells.
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Supplemental Tables
Table 5.
qRT-PCR validation of genes that are differentially regulated in CRLF2 B-ALL cells
expanded in +T as compared to –T xenograft mice. The table shows the list of genes
that were selected from the microarray dataset for validation by qRT-PCR analysis and
their respective fold changes as determined by microarray and by qRT-PCR. The first 7
genes are up-regulated, while the last 7 genes are down-regulated.
Gene

Microarray
(fold change)

qRT-PCR
(fold change)

BIVM
PTH2
FOSL2
RAMP1
SLC4A8
NR4A2
KCNH8

4.440
3.477
2.793
2.725
2.628
2.138
2.154

6.907
2.784
1.843
2.227
6.417
3.548
2.355

THSD7A
RAB26
RGS1
NELL1
MDF1
KREMEN2
CPNE8

–3.628
–2.727
–2.749
–3.586
–2.168
–2.336
–3.008

–6.648
–2.726
–2.498
–3.143
–7.621
–2.003
–4.695
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Table 6: Genes regulated downstream of mTOR signaling. GSEA data summary table
shows genes that are part of the mTOR gene set which were enriched in CRLF2 B-ALL
cells expanded in +T mice as compared to –T mice. Genes are listed in order of increasing
enrichment score (ES).
Gene Symbol
Rank in
Rank
Running ES
Core
Gene List
Metric Score
Enrichment
ECHDC2
FBLN5
BIN2
CD1A
CD1B
EFHC1
POLH
SPRY1
GPA33
ZNF14
H1F0
ZBTB20
ANXA5
PCNXL2
CBX7
BAALC
NFE2
RAG1
PBXIP1
HBP1
TNRC6B
SLC2A11
GIMAP6
MME
HHAT
GALNT7
TPM2
TXNIP
GCC2
REL
SUV420H1
ZNF673
SENP7
SLC35D1
PNRC1
TRIOBP
SYNE2
YPEL5
CBFA2T3
ZNF682
DNTT
CD1E
RAG2
CHIC2
RCOR3
KIAA0355
TPP1
DMXL1
WDR45
ZXDC
CCNG2
MARCH8
BCOR
ZNF180
HIST1H2AC
SLC23A2

148
176
275
291
463
721
800
946
973
1165
1219
1232
1238
1293
1405
1442
1606
1610
1705
1721
1854
1901
1966
1976
1984
2003
2041
2069
2090
2151
2285
2306
2310
2381
2432
2437
2453
2507
2519
2527
2535
2539
2577
2670
2674
2741
2818
2834
2848
2875
2913
2986
3024
3026
3058
3078

0.690
0.662
0.560
0.548
0.451
0.361
0.343
0.304
0.296
0.252
0.242
0.238
0.236
0.224
0.205
0.198
0.172
0.171
0.159
0.157
0.139
0.134
0.129
0.128
0.127
0.125
0.121
0.119
0.117
0.112
0.100
0.099
0.098
0.094
0.091
0.091
0.090
0.087
0.087
0.087
0.086
0.086
0.084
0.079
0.079
0.076
0.073
0.072
0.071
0.070
0.068
0.066
0.064
0.064
0.063
0.063
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0.0435
0.0935
0.1304
0.1723
0.1955
0.2054
0.2268
0.2402
0.2616
0.2677
0.2829
0.3008
0.3189
0.3326
0.3407
0.3537
0.3555
0.3687
0.3745
0.3857
0.3872
0.3945
0.4000
0.4094
0.4189
0.4273
0.4342
0.4415
0.4493
0.4538
0.4521
0.4584
0.4659
0.4683
0.4719
0.4787
0.4847
0.4878
0.4938
0.5001
0.5064
0.5129
0.5168
0.5164
0.5224
0.5236
0.5239
0.5284
0.5331
0.5367
0.5394
0.5394
0.5418
0.5468
0.5495
0.5531

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Supplemental References
1.

Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, et al. IL-7
Dependence in human B lymphopoiesis increases during progression of ontogeny
from cord blood to bone marrow. Journal of immunology. 2009 Apr
1;182(7):4255-66.

2.

Meng X, Neises A, Su RJ, Payne KJ, Ritter L, Gridley DS, et al. Efficient
reprogramming of human cord blood CD34+ cells into induced pluripotent stem
cells with OCT4 and SOX2 alone. Mol Ther. 2012 Feb;20(2):408-16.

3.

Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, et al.
Mobilization, collection, and processing of peripheral blood stem cells in
individuals with sickle cell trait. Blood. 2002 Feb 1;99(3):850-5.

4.

Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model
for gene expression analysis. Bioinformatics. 2006 May 1;22(9):1111-21.

5.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al.
PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. Nat Genet. 2003 Jul;34(3):26773.

6.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et
al. Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct
25;102(43):15545-50.

148

APPENDIX B (CHAPTER 3)
SUPPLEMENTAL MATERIALS
Supplemental Methods
Human Samples
Umbilical cord blood (CB) and bone marrow (BM) were obtained in accordance
with protocols approved by the Loma Linda University Institutional Review Board (IRB)
and with the Helsinki Declaration of 1975, as revised in 2008. Umbilical cord blood (CB)
was obtained from placentas after caesarean section delivery of full-term neonates at
Loma Linda University Medical Center. Mononuclear cells were isolated using FicollPaque Plus (GE Healthcare Bio-Sciences, AB) or by red blood cell (RBC) lysis (1).
CD34+ cells were isolated by magnetic separation with CD34+ microbeads (Miltenyi
Biotec, Auburn, CA) and stored in liquid nitrogen for subsequent use. Pediatric bone
marrow (BM) samples were obtained as waste samples remaining after clinical
procedures under an LLU Institutional Review Board (IRB) approved protocol. Adult
BM and stromal cells were purchased from Lonza Inc. (Walkersville, MD). Stromal cells
were isolated from pediatric and adult BM as previously described (2) and maintained in
IMDM medium supplemented with 15% horse serum, 15% FBS, hydrocortisone, 2mercaptoethanol, penicillin-streptomycin and L-glutamine.
In vitro Co-cultures
Human only in vitro co-cultures were initiated as previously described (3).
Briefly, CB CD34+ cells were seeded onto pre-plated primary human BM stromal cells,
at 10,000 to 20,000 cells per well in 96-well plates. For some experiments, numbers were
scaled up to give equivalent cell densities in 6-well and 12-well plates. Cultures were
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maintained in RPMI 1640 medium (Irvine Scientific, Santa Ana, CA) supplemented with
penicillin/streptomycin, L-glutamine, 50 uM 2-mercaptoethanol and 5 % human AB
serum lot tested to support human B cell production (Omega Scientific, Tarzana, CA).
All cultures, including control, were supplemented with IL-3 (1 ng/ml; first week only)
and Flt-3 Ligand (1 ng/ml, continuously). For selective cytokine stimulation TSLP (10
ng/ml) and/or IL-7 (5 ng/ml) or no cytokines (control cultures) were added. All cytokines
were from R&D Systems Inc. (Minneapolis, MN). If TSLP or IL-7 was not added,
cultures were further supplemented with an anti-human neutralizing antibody to counter
activity of any endogenously produced TSLP or IL-7. Cultures without a specific
neutralizing antibody (anti-IL-7 and/or anti-TSLP) were supplemented with an isotypematched control for the neutralizing antibody. Anti-human neutralizing or control
antibody for IL-7 was used at 10 ng/ml (BD Pharmingen, Franklin Lakes, NJ).). Antihuman neutralizing or control antibody for TSLP was used at 1 ug/ml (R&D Systems and
Jackson ImmunoResearch, West Grove, PA). Media, cytokines, and antibodies were
replenished weekly. Cultures were maintained for three weeks, and then harvested. For
BrdU incorporation, selective cytokine cultures were labeled with 10 M BrdU (SigmaAldrich, St. Louis, MO) for the final 24 hours of culture.

Flow Cytometry
For detection of surface antigens, cells were stained using standard flow
cytometry protocols, followed by fixation and permeabilization as described below to
detect intracellular antigens. To discriminate living from dying cells, in some
experiments, cells were stained with fixable viability dyes (eBioscience, San Diego, CA),
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per  manufacturer’s  instructions.  Apoptosis  was  quantified by flow cytometry using
Annexin-V FITC (Biolegend, San Diego, CA) and 7-AAD (eBioscience, San Diego, CA)
according  to  manufacturer’s  instructions.
To assess intracellular IgM, Ki-67, Bcl-2, Bcl-xL, and Mcl-1, the Fix & Perm®
cell fixation and permeabilization kit (Life Technologies, Grand Island, NY)) was used
according  to  manufacturer’s  instructions.  All  antibodies  were  monoclonal,  anti-human
antibodies, unless otherwise stated. Intranuclear detection of BrdU was performed using
BrdU Flow Kit option  no.  2  (BD  Pharmingen)  according  to  manufacturer’s  instructions.
Briefly, cells were harvested, surface stained, washed then fixed with BD
cytofix/cytoperm buffer (BD Biosciences) for 15-30 minutes at room temperature. Cell
suspensions were washed, then stored overnight in freezing medium (90% FBS and 10%
DMSO) at –80ºC. The following day, thawed cells were washed, re-fixed in BD
cytofix/cytoperm buffer and washed with BD perm/wash buffer. Cells were treated with
DNase (300 ug/ml, Sigma-Aldrich) for 1 hour at 37ºC, washed then stained with antiBrdU FITC or isotype-matched control for 20 minutes at room temperature. Cells were
washed then resuspended in 1% PFA for acquisition.
To assess intracellular PAX-5, cells were first surface stained for viability and
surface markers, then fixed and permeabilized with FoxP3 fix/perm buffer (eBioscience)
for 30-60 minutes at 4ºC in the dark. Cells were washed, resuspended in permeabilization
buffer and stained with PAX-5 PE or isotype-matched controls for 30 minutes at room
temperature. Cells were washed then resuspended in 1% PFA for acquisition. In some
experiments, cells were simultaneously stained for PAX-5 and BrdU. In these
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experiments cells were first stained for PAX-5  according  to  manufacturer’s  directions,  
followed  by  BrdU  staining  according  to  manufacturer’s  instructions.

Table 7: List of Antibodies, Clones and Manufacturer Information 2 (chapter 3)
Antibody

Clone

Manufacturer

BrdU FITC

B44

Bcl-2 FITC

Bcl-2/100

Ig κ  light  chain  FITC

G20-193

Ig  λ  light  chain  FITC

JDC-12

IgM PE Cy-5

G20-127

CD19 APC

HIB19

CD34 PerCP

8G12

CD34 APC

8G12

CD34 APC.Cy7

581

IgD PE

IA6-2

Bcl-xL Alexa-fluor 488

54H6

Cell Signaling
(Beverly, MA)

CD19 APC

HIB19

eBioScience (San Diego, CA)

CD19 PE.Cy7

SJ25C1

CD45 PE.Cy7

HI30

CD127 PE

eBioRDR5

Ig  κ  light  chain  eFluor  450

TB28-2

Ig  λ  light  chain  eFluor  450

1-155-2

PAX-5 PE

1H9

Goat anti-rabbit IgG Alexa Fluor 647

BD Biosciences (San Jose, CA)

Biolegend (San Diego, CA)
Technology

Life Technologies (Molecular
Probes) (Grand Island, NY)

Anti-Mouse CD45 FITC

30F11

CD19 APC

LT19

CD34 APC

AC136

CD127 PE

MB15-18C9

Polyclonal Mcl-1

S-19
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Miltenyi Biotec (Auburn, CA)

Santa Cruz Biotechnology

Polymerase Chain Reaction
Total RNA was extracted from 8 to 9 x 105 human stromal cells with RNA-STAT
60 reagent (Tel-Test Inc., Friendswood, TX). cDNA was synthesized using Omniscript
Reverse Transcriptase (Qiagen, Valencia, CA). The expression of TSLP, IL-7 and -2
microglobulin as a control, were assessed by touch down PCR. The primers used were:
TSLP  forward  5’-TCG TAA ACT TTG CCG CCT AT-3’  and  reverse  5’-TGG TGC TGT
GAA ATA TGA CCA-3’  (324  bp);;  IL-7  forward  5’- CTC CCC TGA TCC TTG TTC TG
and  reverse  5’- TCA TTA TTC AGG CAA TTG CTA CC-3’ (151 bp); -2
microglobulin  forward  5’-CTC GCG CTA CTC TCT CTT TC-3’  and  reverse  5’-CAT
GTC TCG ATC CCA CTT AAC-3’  primers.
Touch-down PCR conditions for TSLP were as follows: 95°C for 5 min (1 cycle);
95°C for 1 min, 61°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 30
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2
cycles); 95°C for 1 min, 55°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C
for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 51°C for 30 sec. 72°C for 1 min
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.
Touchdown PCR conditions for IL-7 were as follows: 95°C for 5 min (1 cycle);
95°C for 1 min, 63°C for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 61°C for 45
sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 59°C for 45 sec, 72°C for 1 min (2
cycles); 95°C for 1 min, 57°C for 30 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 55°C
for 45 sec. 72°C for 1 min (2 cycles); 95°C for 1 min, 53°C for 45 sec. 72°C for 1 min
(30 cycles); 72°C for 10 min (1 cycle); and final hold step of 4°C.
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Amplified PCR products were visualized with a 2.2% FlashGel (Lonza,
Walkerswood, MD). PCR products were purified with QIAquick PCR purification kit
(Qiagen, Valencia, CA) and sequenced at the Genomics Core (University of California,
Riverside, CA).
Animal Studies
Studies were performed using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory). Mice were housed under specific pathogen-free conditions in the
Loma Linda University animal facility and studied in accordance with an Institutional
Animal Care and Use Committee (IACUC) approved protocols. Mice were transplanted
by tail vein injection with freshly thawed, CB CD34+ cells after sub-lethal irradiation at
225 rads. Mice were engineered by intraperitoneal injection with HS-27 stromal cells
(ATCC, Manassas, VA) that had been transduced to express human TSLP (+T mice) or
transduced with empty vector (–T mice) as previously described (4). Transduction of
stroma and injection of stromal cell is described in the companion paper. NSG mice were
euthanized by CO2 asphyxiation, five to seven weeks after CB CD34+ transplantation
and bone marrow and spleen were harvested. Samples were lysed of red blood cells and
then frozen or stained immediately for flow cytometry analysis.
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